


**CUMULATIVE  
SUPPLEMENT 05  
May 2006**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**26<sup>th</sup> EDITION**

**Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs**

2006

Prepared By  
Office of Generic Drugs  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**26<sup>th</sup> EDITION**

**Cumulative Supplement 05**

**May 2006**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION .....	iii
1.1 How to use the Cumulative Supplement .....	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition .....	v
1.4 Report of Counts for the Prescription Drug Product List .....	vi
1.5 Zocor (simvastatin) Patent Relisting.....	vii
1.6 Cumulative Supplement Legend .....	vi
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**Note:**

Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**26<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 05**

**May 2006**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

APOTEX CORP  
(APOTEX)  
APOTEX CORP  
(APOTEX)

APOTEX INC ETOBICOKE SITE  
(APOTEX INC)  
APOTEX INC RICHMOND HILL  
(APOTEX INC)

APOTEX INC (APOTEX)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX)	APOTEX INC RICHMOND HILL (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC RICHMOND HILL (APOTEX INC)
AVENTIS PHARMACEUTICALS INC (AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC (AVENTIS PHARMS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANKYO PHARMA INC (SANKYO)	DAIICHI SANKYO INC (DAIICHI SANKYO)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
STERIS LABORATORIES INC (STERIS)	(SANOFI AVENTIS US) WATSON LABORATORIES INC (WATSON)
TRIGEN LABORATORIES INC (TRIGEN)	JUBILANT PHARMACEUTICALS INC (JUBILANT PHARMS)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

### 1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB <http://www.fda.gov/cder/ob/default.htm>), has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## **1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST**

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2005</u>	<u>MAR 2006</u>	<u>SEP 2006</u>	<u>DEC 2006</u>
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428	2461		
	(21.4%)	(21.4%)		
MULTISOURCE	8851	8937		
	(77.9%)	(77.8%)		
THERAPEUTICALLY EQUIVALENT	8642	8730		
	(76.04%)	(76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209	207		
	(1.8%)	(1.8%)		
EXCEPTIONS <sup>1</sup>	89	89		
	(0.8%)	(0.8%)		
NEW MOLECULAR ENTITIES				
APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

#### 1.5 ZOCOR (SIMVASTATIN) PATENT RELISTING

U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v. Leavitt*, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in *Approved Drug Products with Therapeutic Equivalence Ratings* until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

#### 1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.



New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2006

1-1

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

SECTRAL

>A>	AB	DR REDDYS LABS INC	EQ 200MG BASE	N18917 001	Dec 28, 1984	May	CAHN
>A>	AB	+	EQ 400MG BASE	N18917 003	Dec 28, 1984	May	CAHN
>D>	AB	ESP PHARMA	EQ 200MG BASE	N18917 001	Dec 28, 1984	May	CAHN
>D>	AB	+	EQ 400MG BASE	N18917 003	Dec 28, 1984	May	CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AB	+	MIKART	650MG;50MG	N89988 001	Oct 26, 1992	Jan	CRLD
		SEDAPAP					
		@ MAYRAND	650MG;50MG	N88944 001	Oct 17, 1985	Jan	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@ CLONMEL	120MG/5ML;12MG/5ML	N40098 001	Sep 20, 1996	Jan	DISC
--	--	-----------	--------------------	------------	--------------	-----	------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	TEVA	300MG;60MG	N88629 001	Mar 06, 1985	Apr	CRLD
----	---	------	------------	------------	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>		ENDO PHARMS	400MG;5MG	N40288 001	Nov 27, 1998	May	CTNA
>D>	+		400MG;7.5MG	N40288 002	Nov 27, 1998	May	CTNA
>D>	+		400MG;10MG	N40288 003	Nov 27, 1998	May	CTNA
>D>		@	500MG;7.5MG	N40280 001	Sep 30, 1998	Feb	DISC
		@	650MG;7.5MG	N40280 002	Sep 30, 1998	Feb	DISC
		@	650MG;10MG	N40280 003	Sep 30, 1998	Feb	DISC
		@	750MG;7.5MG	N40281 002	Sep 30, 1998	Feb	DISC
		MIKART	300MG;5MG	N40658 001	Jan 19, 2006	Jan	NEWA
	+		300MG;7.5MG	N40556 002	Mar 24, 2006	Mar	NEWA
AA		VINTAGE PHARMS	325MG;5MG	N40655 001	Jan 19, 2006	Jan	NEWA
AA			325MG;7.5MG	N40656 001	Jan 19, 2006	Jan	NEWA
		HY-PHEN					
		@ ASCHER	500MG;5MG	N87677 001	May 03, 1982	Mar	DISC
>A>		ZYDONE					
>A>	+	ENDO PHARMS	400MG;5MG	N40288 001	Nov 27, 1998	May	CTNA
>A>	+		400MG;7.5MG	N40288 002	Nov 27, 1998	May	CTNA
>A>	+		400MG;10MG	N40288 003	Nov 27, 1998	May	CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	+	MIKART	400MG;2.5MG	N40679 001	May 16, 2006	May	NEWA
	+		400MG;5MG	N40687 001	Apr 27, 2006	Apr	NEWA
	+		400MG;7.5MG	N40698 001	Apr 27, 2006	Apr	NEWA
	+		400MG;10MG	N40692 001	Apr 27, 2006	Apr	NEWA
			500MG;10MG	N40676 001	Apr 19, 2006	Apr	NEWA

ACETAZOLAMIDE

	TABLET; ORAL							
	ACETAZOLAMIDE							
AB	+	TARO	250MG	N40195	002	May 28, 1997	Mar	CRLD
		DIAMOX						
		@ DURAMED PHARMS BARR	125MG	N08943	001		Mar	DISC
		@	250MG	N08943	002		Mar	DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

	SOLUTION/DROPS; OTIC							
	HYDROCORTISONE AND ACETIC ACID							
AT		VINTAGE	2%;1%	N40609	001	Feb 06, 2006	Jan	NEWA

ACYCLOVIR

	CAPSULE; ORAL							
	ACYCLOVIR							
>D>	AB	AAIPHARMA LLC	200MG	N74833	001	Apr 22, 1997	May	CAHN
>A>	AB	CLONMEL HLTHCARE	200MG	N74833	001	Apr 22, 1997	May	CAHN
	TABLET; ORAL							
	ACYCLOVIR							
>D>	AB	AAIPHARMA LLC	400MG	N74946	001	Nov 19, 1997	May	CAHN
>D>	AB		800MG	N74946	002	Nov 19, 1997	May	CAHN
>A>	AB	CLONMEL HLTHCARE	400MG	N74946	001	Nov 19, 1997	May	CAHN
>A>	AB		800MG	N74946	002	Nov 19, 1997	May	CAHN

ALBUTEROL

	AEROSOL, METERED; INHALATION							
	ALBUTEROL							
		@ GENPHARM	0.09MG/INH	N73045	001	Aug 19, 1997	Feb	DISC
		@ PLIVA	0.09MG/INH	N74072	001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

	SOLUTION; INHALATION							
	ALBUTEROL SULFATE							
AN		RXELITE	EQ 0.083% BASE	N77569	001	Apr 04, 2006	Mar	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE; SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

	INJECTABLE; INJECTION							
	INFUVITE ADULT							
+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML		N21163	001	May 18, 2000	Jan	CAHN
	INJECTABLE; IV (INFUSION)							
	INFUVITE ADULT							
+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30UGM/ML		N21559	001	Jun 16, 2003	Jan	CAHN

ALPRAZOLAM

	TABLET, EXTENDED RELEASE; ORAL							
	ALPRAZOLAM							
AB		MYLAN	0.5MG	N77391	002	Jan 26, 2006	Jan	NEWA
AB			1MG	N77391	003	Jan 26, 2006	Jan	NEWA

## TABLET, EXTENDED RELEASE; ORAL

## ALPRAZOLAM

AB	MYLAN	2MG	N77391 004	Jan 26, 2006	Jan	NEWA
AB		3MG	N77391 001	Jan 26, 2006	Jan	NEWA
XANAX XR						
AB	PHARMACIA AND UPJOHN	0.5MG	N21434 001	Jan 17, 2003	Jan	CFTG
AB		1MG	N21434 002	Jan 17, 2003	Jan	CFTG
AB		2MG	N21434 003	Jan 17, 2003	Jan	CFTG
AB	+	3MG	N21434 004	Jan 17, 2003	Jan	CFTG

AMANTADINE HYDROCHLORIDE

## CAPSULE; ORAL

## AMANTADINE HYDROCHLORIDE

AB	AMIDE PHARM	100MG	N77659 001	Feb 23, 2006	Feb	NEWA
----	-------------	-------	------------	--------------	-----	------

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

## CAPSULE; ORAL

## LOTREL

## NOVARTIS

		EQ 5MG BASE;40MG	N20364 007	Apr 11, 2006	Apr	NEWA
		EQ 10MG BASE;20MG	N20364 005	Jun 20, 2002	Apr	CRLD
+		EQ 10MG BASE;40MG	N20364 006	Apr 11, 2006	Apr	NEWA

AMMONIUM LACTATE

## CREAM; TOPICAL

## AMMONIUM LACTATE

AB	PADDOCK	EQ 12% BASE	N76829 001	Feb 07, 2006	Jan	NEWA
----	---------	-------------	------------	--------------	-----	------

AMOXICILLIN

## CAPSULE; ORAL

## AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	N62058 001		Jan	CAHN
AB		500MG	N62058 002		Jan	CAHN

## FOR SUSPENSION; ORAL

## AMOXICILLIN

AB	AM ANTIBIOTICS	125MG/5ML	N62059 001		Jan	CAHN
AB		250MG/5ML	N62059 002		Jan	CAHN

## TABLET; ORAL

## AMOXICILLIN

AB	HIKMA	875MG	N65255 001	Mar 29, 2006	Mar	NEWA
----	-------	-------	------------	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## TABLET; ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D>	AB	ABRIKA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472 001	Sep 30, 2003	May	CAHN
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472 002	Sep 30, 2003	May	CAHN
>D>	AB		5MG;5MG;5MG;5MG	N40472 003	Sep 30, 2003	May	CAHN
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472 004	Sep 30, 2003	May	CAHN
>A>	AB	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472 001	Sep 30, 2003	May	CAHN
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472 002	Sep 30, 2003	May	CAHN
>A>	AB		5MG;5MG;5MG;5MG	N40472 003	Sep 30, 2003	May	CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472 004	Sep 30, 2003	May	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS	EQ 250MG BASE	N61602 001	Jan	CAHN
@	EQ 500MG BASE	N61602 002	Jan	CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601 001	Jan	CAHN
@	EQ 250MG BASE/5ML	N61601 002	Jan	CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON	50MG/VIAL	N21632 001	Feb 17, 2006	Feb	NEWA
-----------	-----------	------------	--------------	-----	------

ANISINDIONE

TABLET; ORAL

MIRADON

@ SCHERING	50MG	N10909 003	Jan	DISC
------------	------	------------	-----	------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

SEPTOCAINE

DEPROCO	4%;EQ 0.005MG BASE/ML	N22010 001	Mar 30, 2006	Mar	NEWA
+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001	Apr 03, 2000	Mar	CPOT

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML)	N22010 001	Mar 30, 2006	Apr	CAIN
+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001	Apr 03, 2000	Apr	CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	Feb 21, 2001	Jan	CAHN
----------	---	------------	--------------	-----	------

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001	Jan 29, 2004	Jan	CAHN
----------	---	------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001	Mar 05, 1999	Feb	DISC
FIORINAL W/CODEINE					
AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	Oct 26, 1990	Apr	CTNA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL  
 PERCODAN-DEMI  
 @ ENDO PHARMS 325MG;2.25MG;0.19MG N07337 005 Feb DISC

ATOVAQUONE

>D> TABLET; ORAL  
 >D> MEPRON  
 >D> + GLAXOSMITHKLINE 250MG N20259 001 Nov 25, 1992 May DISC  
 >A> @ 250MG N20259 001 Nov 25, 1992 May DISC

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL  
 SPECTROBID  
 @ PFIZER 125MG/5ML N50556 001 Mar 23, 1982 Feb DISC  
 TABLET; ORAL  
 SPECTROBID  
 @ PFIZER 400MG N50520 001 Feb DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL  
 BENAZEPRIL HYDROCHLORIDE  
 AB APOTEX INC 5MG N77128 001 Mar 08, 2006 Feb NEWA  
 AB 10MG N77128 002 Mar 08, 2006 Feb NEWA  
 AB 20MG N77128 003 Mar 08, 2006 Feb NEWA  
 AB 40MG N77128 004 Mar 08, 2006 Feb NEWA  
 AB BIOKEY 5MG N76820 001 Feb 03, 2006 Jan NEWA  
 AB 10MG N76820 002 Feb 03, 2006 Jan NEWA  
 AB 20MG N76820 003 Feb 03, 2006 Jan NEWA  
 AB 40MG N76820 004 Feb 03, 2006 Jan NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL  
 BENZPHETAMINE HYDROCHLORIDE  
 AA PADDOCK 50MG N40578 001 Apr 17, 2006 Apr NEWA  
 DIDREX  
 AA + PHARMACIA AND UPJOHN 50MG N12427 002 Apr CFTG

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
 EMETE-CON  
 @ PFIZER EQ 50MG BASE/VIAL N16820 001 Mar DISC

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL  
 CYSTADANE  
 + JAZZ 1GM/SCOOPFUL N20576 001 Oct 25, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL  
 TACLONEX  
 + LEO PHARM PRODS 0.064%;0.005% N21852 001 Jan 09, 2006 Jan NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

>D>	+	ALLERGAN	0.15%	N21262 001	Mar 16, 2001	May	CTEC
>A>	AT	+	0.15%	N21262 001	Mar 16, 2001	May	CTEC

BRIMONIDINE TARTRATE

	AT	AKORN	0.2%	N76439 001	Mar 14, 2006	Feb	NEWA
>A>	AT	ALCON RES	0.15%	N21764 001	May 22, 2006	May	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

	+	ALCON	1%	N20816 001	Apr 01, 1998	Feb	CAHN
--	---	-------	----	------------	--------------	-----	------

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT

	+	ASTRAZENECA	0.032MG/INH	N20746 001	Oct 01, 1999	Mar	CRLD
		@	0.064MG/INH	N20746 002	Oct 01, 1999	Mar	DISC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	+	BEDFORD	0.25MG/ML	N74441 001	Jan 27, 1995	Feb	CRLD
		BUMEX					
		@ ROCHE	0.25MG/ML	N18226 001	Feb 28, 1983	Feb	DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

	+	HOSPIRA	0.5%	N22046 002	Jul 13, 1983	Apr	NEWA
--	---	---------	------	------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

	+	HOSPIRA	0.5%;EQ 0.009MG BASE/ML	N22046 001	Jul 13, 1983	Apr	NEWA
--	---	---------	-------------------------	------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB		APOTEX INC	75MG	N76143 001	Jan 17, 2006	Jan	NEWA
AB			100MG	N76143 002	Jan 17, 2006	Jan	NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

	+	PDL BIOPHARMA INC	6MG/ML	N20954 001	Feb 04, 1999	Jan	CAHN
--	---	-------------------	--------	------------	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

	@	NOVARTIS	100MG;2MG	N09000 002		Feb	DISC
--	---	----------	-----------	------------	--	-----	------

MIGERGOT

	+	G AND W LABS	100MG;2MG	N86557 001	Oct 04, 1983	Feb	CRLD
--	---	--------------	-----------	------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX

+ LEO PHARM 0.005% N20554 001 Jul 22, 1996 Feb CAHN

OINTMENT; TOPICAL

DOVONEX

+ LEO PHARM 0.005% N20273 001 Dec 29, 1993 Feb CAHN

SOLUTION; TOPICAL

DOVONEX

+ LEO PHARM 0.005% N20611 001 Mar 03, 1997 Feb CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION

MIACALCIN

+ NOVARTIS 200 IU/ML N17808 002 Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB ROXANE 0.25UGM N76917 001 Mar 27, 2006 Mar NEWA

INJECTABLE; INJECTION

CALCITRIOL

AP GENIX THERAP 0.001MG/ML N77102 001 Feb 08, 2006 Jan NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

&gt;D&gt; + ASTRAZENECA 8MG N20838 002 Jun 04, 1998 May CRLD

&gt;A&gt; 8MG N20838 002 Jun 04, 1998 May CRLD

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ CLONMEL HLTHCARE 12.5MG N74423 001 Feb 13, 1996 Jan DISC

@ 25MG N74423 002 Feb 13, 1996 Jan DISC

@ 50MG N74423 003 Feb 13, 1996 Jan DISC

@ 100MG N74423 004 Feb 13, 1996 Jan DISC

@ ENDO LABS 12.5MG N74418 001 Feb 13, 1996 Feb DISC

@ 25MG N74418 002 Feb 13, 1996 Feb DISC

@ 50MG N74418 003 Feb 13, 1996 Feb DISC

@ 100MG N74418 004 Feb 13, 1996 Feb DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ ENDO LABS 25MG;15MG N74788 001 Dec 29, 1997 Feb DISC

@ 25MG;25MG N74788 002 Dec 29, 1997 Feb DISC

@ 50MG;15MG N74788 004 Dec 29, 1997 Feb DISC

@ 50MG;25MG N74788 003 Dec 29, 1997 Feb DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP WATSON LABS 50MG/VIAL N77383 001 Jan 27, 2006 Jan NEWA



## INJECTABLE; INJECTION

## CARBOPLATIN

AP	WATSON LABS	150MG/VIAL	N77383 002	Jan 27, 2006	Jan	NEWA
AP		450MG/VIAL	N77383 003	Jan 27, 2006	Jan	NEWA

## INJECTABLE; IV (INFUSION)

## CARBOPLATIN

	@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Feb	DISC
AP		EQ 50MG/5ML (10MG/ML)	N77266 001	Feb 15, 2006	Jan	NEWA
	@	EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Feb	DISC
AP		EQ 150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jan	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jan	NEWA
AP		EQ 600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jan	NEWA
AP	BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jan	NEWA

CASPOFUNGIN ACETATE

## INJECTABLE; IV (INFUSION)

## CANCIDAS

>A>	+	MERCK	50MG/VIAL	N21227 001	Jan 26, 2001	May	CAHN
>A>	+		70MG/VIAL	N21227 002	Jan 26, 2001	May	CAHN
>D>	+	MERCK RES	50MG/VIAL	N21227 001	Jan 26, 2001	May	CAHN
>D>	+		70MG/VIAL	N21227 002	Jan 26, 2001	May	CAHN

CEFACTOR

## TABLET, EXTENDED RELEASE; ORAL

## CEFACTOR

>D>	AB	+	IVAX PHARMS	EQ 500MG BASE	N65057 001	Jan 05, 2001	May	CAHN
>A>	AB	+	PAR PHARM	EQ 500MG BASE	N65057 001	Jan 05, 2001	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

## CAPSULE; ORAL

## CEFADROXIL

AB	+	IVAX PHARMS	EQ 500MG BASE	N62766 001	Mar 03, 1987	Mar	CRLD
AB		TEVA PHARMS	EQ 500MG BASE	N65282 001	Jan 20, 2006	Jan	NEWA
AB		WESTWARD	EQ 500MG BASE	N65311 001	Feb 07, 2006	Jan	NEWA

## DURICEF

## @ WARNER CHILCOTT

		EQ 500MG BASE	N50512 001		Jan	DISC
--	--	---------------	------------	--	-----	------

## FOR SUSPENSION; ORAL

## CEFADROXIL

		RANBAXY	EQ 125MG BASE/5ML	N65115 001	Mar 26, 2003	Feb	CTEC
AB		TEVA PHARMS	EQ 250MG BASE/5ML	N65278 001	Jan 20, 2006	Jan	NEWA
AB			EQ 500MG BASE/5ML	N65278 002	Jan 20, 2006	Jan	NEWA

## DURICEF

## @ WARNER CHILCOTT

		EQ 125MG BASE/5ML	N50527 002		Feb	DISC
--	--	-------------------	------------	--	-----	------

## TABLET; ORAL

## CEFADROXIL

AB		HIKMA	EQ 1GM BASE	N65260 001	Mar 30, 2006	Mar	NEWA
AB	+	IVAX PHARMS	EQ 1GM BASE	N62774 001	Apr 08, 1987	Feb	CRLD

## DURICEF

## @ WARNER CHILCOTT

		EQ 1GM BASE	N50528 001		Jan	DISC
--	--	-------------	------------	--	-----	------

CEFAZOLIN SODIUM

## INJECTABLE; INJECTION

## CEFAZOLIN AND DEXTROSE

>D>	+	B BRAUN	EQ 500MG BASE/VIAL	N50779 001	Jul 27, 2000	May	DISC
>A>	@		EQ 500MG BASE/VIAL	N50779 001	Jul 27, 2000	May	DISC

CEFDINIR

## CAPSULE; ORAL

>A>		CEFDINIR						
>A>	AB	LUPIN	300MG	N65264	001	May 19, 2006	May	NEWA
		OMNICEF						
>D>	+	ABBOTT	300MG	N50739	001	Dec 04, 1997	May	CFTG
>A>	AB	+	300MG	N50739	001	Dec 04, 1997	May	CFTG

## FOR SUSPENSION; ORAL

>A>		CEFDINIR						
>A>	AB	LUPIN (USA)	125MG/5ML	N65259	001	May 31, 2006	May	NEWA
		OMNICEF						
>D>		ABBOTT	125MG/5ML	N50749	001	Dec 04, 1997	May	CFTG
>A>	AB		125MG/5ML	N50749	001	Dec 04, 1997	May	CFTG

CEFOTAXIME SODIUM

## INJECTABLE; INJECTION

>D>		CEFOTAXIME AND DEXTROSE	2.4% IN PLASTIC CONTAINER					
>D>	+	B BRAUN	EQ 2GM BASE	N50792	001	Jul 29, 2004	May	DISC
>A>	@		EQ 2GM BASE	N50792	001	Jul 29, 2004	May	DISC
>D>		CEFOTAXIME AND DEXTROSE	3.9% IN PLASTIC CONTAINER					
>D>	+	B BRAUN	EQ 1GM BASE	N50792	002	Jul 29, 2004	May	DISC
>A>	@		EQ 1GM BASE	N50792	002	Jul 29, 2004	May	DISC

CEFOXITIN SODIUM

## INJECTABLE; INJECTION

## CEFOXITIN

AP		ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313	001	Jan 23, 2006	Jan	NEWA
AP			EQ 2GM BASE/VIAL	N65313	002	Jan 23, 2006	Jan	NEWA
AP			EQ 10GM BASE/VIAL	N65312	001	Feb 13, 2006	Jan	NEWA

## CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP		B BRAUN	EQ 1GM BASE/VIAL	N65214	001	Mar 10, 2006	Feb	NEWA
AP			EQ 2GM BASE/VIAL	N65214	002	Mar 10, 2006	Feb	NEWA

>D> CEFTAZIDIME (ARGININE FORMULATION)

## INJECTABLE; INJECTION

## CEPTAZ

>D>		CEPTAZ						
>D>	+	GLAXOSMITHKLINE	1GM/VIAL	N50646	002	Sep 27, 1990	May	DISC
>A>	@		1GM/VIAL	N50646	002	Sep 27, 1990	May	DISC
>D>	+		2GM/VIAL	N50646	003	Sep 27, 1990	May	DISC
>A>	@		2GM/VIAL	N50646	003	Sep 27, 1990	May	DISC
>D>	+		10GM/VIAL	N50646	004	Sep 27, 1990	May	DISC
>A>	@		10GM/VIAL	N50646	004	Sep 27, 1990	May	DISC

CEFTRIAZONE

## INJECTABLE; INJECTION

## CEFTRIAZONE

AP		TEVA	EQ 10GM BASE/VIAL	N65274	001	May 01, 2006	Apr	NEWA
----	--	------	-------------------	--------	-----	--------------	-----	------

CEFTRIAZONE SODIUM

## INJECTABLE; IM-IV

## CEFTRIAZONE

AP		AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245	001	Feb 15, 2006	Jan	NEWA
AP			EQ 500MG BASE/VIAL	N65245	002	Feb 15, 2006	Jan	NEWA
AP			EQ 1GM BASE/VIAL	N65245	003	Feb 15, 2006	Jan	NEWA

## INJECTABLE; IM-IV

## CEFTRIAZONE

AP	AM PHARM PARTNERS	EQ 2GM BASE/VIAL	N65245 004	Feb 15, 2006	Jan	NEWA
----	-------------------	------------------	------------	--------------	-----	------

## INJECTABLE; INJECTION

## CEFTRIAZONE

AP	AM PHARM	EQ 10GM BASE/VIAL	N65252 001	Feb 15, 2006	Jan	NEWA
----	----------	-------------------	------------	--------------	-----	------

>A>	AP	WOCKHARDT	EQ 1GM BASE/VIAL	N65180 001	May 12, 2006	May	NEWA
-----	----	-----------	------------------	------------	--------------	-----	------

CEFUROXIME AXETIL

## TABLET; ORAL

## CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308 001	Mar 29, 2006	Mar	NEWA
----	----------------------	---------------	------------	--------------	-----	------

AB		EQ 250MG BASE	N65308 002	Mar 29, 2006	Mar	NEWA
----	--	---------------	------------	--------------	-----	------

AB		EQ 500MG BASE	N65308 003	Mar 29, 2006	Mar	NEWA
----	--	---------------	------------	--------------	-----	------

CEPHALEXIN

## CAPSULE; ORAL

## CEPHALEXIN

AB	HIKMA	EQ 250MG BASE	N65215 001	Jan 24, 2006	Jan	NEWA
----	-------	---------------	------------	--------------	-----	------

AB		EQ 500MG BASE	N65215 002	Jan 24, 2006	Jan	NEWA
----	--	---------------	------------	--------------	-----	------

## KEFLEX

>A>		ADVANCIS PHARM	EQ 333MG BASE	N50405 004	May 12, 2006	May	NEWA
-----	--	----------------	---------------	------------	--------------	-----	------

>D>	AB	+	EQ 500MG BASE	N50405 003		May	CRLD
-----	----	---	---------------	------------	--	-----	------

>A>	AB		EQ 500MG BASE	N50405 003		May	CRLD
-----	----	--	---------------	------------	--	-----	------

>A>		+	EQ 750MG BASE	N50405 005	May 12, 2006	May	NEWA
-----	--	---	---------------	------------	--------------	-----	------

CEPHRADINE

## CAPSULE; ORAL

## ANSPOR

	@	GLAXOSMITHKLINE	250MG	N61859 001		Mar	DISC
--	---	-----------------	-------	------------	--	-----	------

	@		500MG	N61859 002		Mar	DISC
--	---	--	-------	------------	--	-----	------

>D> CETYL ALCOHOL; COLFOCERIL PALMITATE; TYLOXAPOL

## &gt;D&gt; FOR SUSPENSION; INTRATRACHEAL

## &gt;D&gt; EXOSURF NEONATAL

>D>	+	GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N20044 001	Aug 02, 1990	May	DISC
-----	---	-----------------	-------------------------------	------------	--------------	-----	------

>A>		@	12MG/VIAL;108MG/VIAL;8MG/VIAL	N20044 001	Aug 02, 1990	May	DISC
-----	--	---	-------------------------------	------------	--------------	-----	------

>D> CHLORPROMAZINE

## &gt;D&gt; SUPPOSITORY; RECTAL

## &gt;D&gt; THORAZINE

>D>	+	GLAXOSMITHKLINE	25MG	N09149 024		May	DISC
-----	---	-----------------	------	------------	--	-----	------

>A>		@	25MG	N09149 024		May	DISC
-----	--	---	------	------------	--	-----	------

>D>	+		100MG	N09149 033		May	DISC
-----	---	--	-------	------------	--	-----	------

>A>		@	100MG	N09149 033		May	DISC
-----	--	---	-------	------------	--	-----	------

CHLORPROMAZINE HYDROCHLORIDE

## &gt;D&gt; CAPSULE, EXTENDED RELEASE; ORAL

## &gt;D&gt; THORAZINE

>D>	+	GLAXOSMITHKLINE	200MG	N11120 019		May	DISC
-----	---	-----------------	-------	------------	--	-----	------

>A>		@	200MG	N11120 019		May	DISC
-----	--	---	-------	------------	--	-----	------

>D>	+		300MG	N11120 020		May	DISC
-----	---	--	-------	------------	--	-----	------

>A>		@	300MG	N11120 020		May	DISC
-----	--	---	-------	------------	--	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	PERRIGO	0.77%	N77364	001	Mar 03, 2006	Mar	CAHN
AB	PERRIGO NEW YORK	0.77%	N77364	001	Mar 03, 2006	Feb	NEWA

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	MUTUAL PHARM	50MG	N77208	002	Mar 29, 2006	Mar	NEWA
AB		100MG	N77208	001	Mar 29, 2006	Mar	NEWA
AB	MYLAN	50MG	N77323	002	Apr 20, 2006	Apr	NEWA
AB		100MG	N77323	001	Apr 20, 2006	Apr	NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ ENDO PHARMS

200MG

N74281 001 May 17, 1994 Feb DISC

@

300MG

N74281 002 May 17, 1994 Feb DISC

@

400MG

N74281 003 May 17, 1994 Feb DISC

@

800MG

N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/2ML

N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/5ML

N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

>A>	AA	SILARX	EQ 10MG BASE/5ML	N77629	001	Jun 15, 2006	May	NEWA
-----	----	--------	------------------	--------	-----	--------------	-----	------

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	TARO	EQ 10MG BASE	N77278	001	Mar 22, 2006	Mar	NEWA
AB		EQ 20MG BASE	N77278	002	Mar 22, 2006	Mar	NEWA
AB		EQ 40MG BASE	N77278	003	Mar 22, 2006	Mar	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	N77213	001	Mar 31, 2006	Mar	NEWA
AB		EQ 20MG BASE	N77213	002	Mar 31, 2006	Mar	NEWA
AB		EQ 40MG BASE	N77213	003	Mar 31, 2006	Mar	NEWA

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>A>	AB	WOCKHARDT	250MG	N65266	001	May 31, 2006	May	NEWA
>A>	AB		500MG	N65266	002	May 31, 2006	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

+ RANBAXY

1GM

N65210 001 Jan 26, 2005 Apr CRLD

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	ALTANA	EQ 1% BASE	N65254 001	Feb 14, 2006	Jan	NEWA
----	--------	------------	------------	--------------	-----	------

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

>D>	AT	ALTANA	0.05%	N75391 001	Feb 08, 1999	May	DISC
>A>		@	0.05%	N75391 001	Feb 08, 1999	May	DISC

SPRAY; TOPICAL

CLOBEX

	+	GALDERMA LABS LP	0.05%	N21835 001	Oct 27, 2005	Feb	CAHN
--	---	------------------	-------	------------	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX	EQ 75MG BASE	N76274 001	Jan 20, 2006	Jan	NEWA
----	--------	--------------	------------	--------------	-----	------

PLAVIX

AB	+	SANOFI SYNTHELABO	EQ 75MG BASE	N20839 001	Nov 17, 1997	Jan	CFTG
----	---	-------------------	--------------	------------	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

	+	ALPHARMA US PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	Oct 31, 1984	Jan	CTEC
--	---	--------------------	-----------------------------	------------	--------------	-----	------

PROMETHAZINE VC W/ CODEINE

	@	MORTON GROVE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88896 001	Jan 04, 1985	Jan	DISC
--	---	--------------	-----------------------------	------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE SYRUP

AA	VINTAGE	10MG/5ML;6.25MG/5ML	N40650 001	Jan 31, 2006	Jan	NEWA
----	---------	---------------------	------------	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563 003	Sep 22, 1995	Apr	CFTG
----	----------------------	--------------	------------	--------------	-----	------

AB	+		5GM/PACKET	N17563 004	Sep 22, 1995	Apr	CFTG
----	---	--	------------	------------	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

AB	IMPAX LABS	5GM/PACKET	N77277 002	May 02, 2006	Apr	NEWA
----	------------	------------	------------	--------------	-----	------

AB		5GM/SCOOPFUL	N77277 001	May 02, 2006	Apr	NEWA
----	--	--------------	------------	--------------	-----	------

FLAVORED COLESTID

	PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001		Apr	CRLD
--	----------------------	------------	------------	--	-----	------

CROMOLYN SODIUM

&gt;A&gt; CONCENTRATE; ORAL

&gt;A&gt; GASTROCROM

>A>	+	AZUR PHARMA	100MG/5ML	N20479 001	Feb 29, 1996	May	CDFR
-----	---	-------------	-----------	------------	--------------	-----	------

&gt;D&gt; SOLUTION, CONCENTRATE; ORAL

&gt;D&gt; GASTROCROM

>D>	+	AZUR PHARMA	100MG/5ML	N20479 001	Feb 29, 1996	May	CDFR
-----	---	-------------	-----------	------------	--------------	-----	------

	+		100MG/5ML	N20479 001	Feb 29, 1996	Feb	CAHN
--	---	--	-----------	------------	--------------	-----	------

CYANOCOBALAMIN

GEL, METERED; NASAL  
NASCOBAL

@ QOL MEDCL 0.5MG/INH N19722 001 Nov 05, 1996 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB JUBILANT PHARMS 5MG N77563 001 Apr 19, 2006 Apr NEWA

AB 10MG N77563 002 Apr 19, 2006 Apr NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

AB AMIDE PHARM 5MG N77291 001 Feb 03, 2006 Jan NEWA

AB MUTUAL PHARM 5MG N73541 002 Apr 06, 2006 Mar NEWA

AB MYLAN 5MG N73144 002 Feb 03, 2006 Jan NEWA

AB SANDOZ 5MG N72854 002 Feb 03, 2006 Jan NEWA

AB WATSON LABS 5MG N71611 002 Feb 03, 2006 Jan NEWA

7.5MG N71611 003 Feb 03, 2006 Jan NEWA

FLEXERIL

AB MCNEIL CONS SPECLT 5MG N17821 001 Jan CFTG

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D> @ ABC HOLDING 4MG N88212 001 May 26, 1983 May CAHN

>A> @ TG UNITED LABS 4MG N88212 001 May 26, 1983 May CAHN

CYPROHEPTADINE HYDROCHLORIDE

>A> AA STASON PHARMS 4MG N40644 001 May 30, 2006 May NEWA

DECITABINE

>A> INJECTABLE; INTRAVENOUS

>A> DACOGEN

>A> + MGI PHARMA INC 50MG/VIAL N21790 001 May 02, 2006 May NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP SICOR PHARMS 500MG/VIAL N76806 001 Mar 31, 2006 Mar NEWA

AP 2GM/VIAL N76806 002 Mar 31, 2006 Mar NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ GLADES PHARMS LLC 75MG N50261 001 Mar CAHN

AB 150MG N50261 002 Mar CAHN

AB + 300MG N50261 003 Mar CAHN

@ PROTEIN DESIGN LABS 75MG N50261 001 Feb CAHN

AB 150MG N50261 002 Feb CAHN

AB + 300MG N50261 003 Feb CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX-D 12 HOUR

+ SCHERING 2.5MG;120MG N21313 001 Feb 01, 2006 Feb NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

@ BEDFORD 0.004MG/ML N74575 001 Feb 18, 2000 Jan DISC

DESMOPRESSIN ACETATE PRESERVATIVE FREE

@ BEDFORD 0.004MG/ML N74574 001 Feb 18, 2000 Jan DISC

TABLET; ORAL

DESMOPRESSIN ACETATE

AB APOTEX 0.1MG N77414 001 Mar 07, 2006 Feb NEWA

AB 0.2MG N77414 002 Mar 07, 2006 Feb NEWA

AB TEVA PHARMS 0.1MG N77122 001 Jan 25, 2006 Jan NEWA

AB 0.2MG N77122 002 Jan 25, 2006 Jan NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB + DURAMED 0.15MG,N/A;0.02MG,0.01MG N20713 001 Apr 22, 1998 Feb CAHN

AB + 0.15MG,N/A;0.02MG,0.01MG N20713 001 Apr 22, 1998 Feb CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

AP BAXTER HLTHCARE EQ 10MG PHOSPHATE/ML N87702 001 Sep 07, 1982 Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

@ ENDO PHARMS 5MG N40299 001 May 13, 1999 Feb DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA VINTAGE 15MG/5ML;6.25MG/5ML N40649 001 Feb 14, 2006 Jan NEWA

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB VINTAGE PHARMS 2MG N77749 001 Mar 31, 2006 Mar NEWA

AB 5MG N77749 002 Mar 31, 2006 Mar NEWA

AB 10MG N77749 003 Mar 31, 2006 Mar NEWA

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

&gt;D&gt; AB + SANDOZ 75MG N74394 001 Nov 30, 1995 May CRLD

&gt;A&gt; AB 75MG N74394 001 Nov 30, 1995 May CRLD

VOLTAREN

&gt;D&gt; @ NOVARTIS 75MG N19201 003 Jul 28, 1988 May CMFD

&gt;A&gt; AB + 75MG N19201 003 Jul 28, 1988 May CMFD

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

&gt;D&gt; @ ABC HOLDING 25MG N88267 001 Aug 25, 1983 May CAHN

## TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

>D>	@ ABC HOLDING	25MG	N88268 001	Aug 25, 1983	May	CAHN
>A>	@ TG UNITED LABS	25MG	N88267 001	Aug 25, 1983	May	CAHN
>A>	@	25MG	N88268 001	Aug 25, 1983	May	CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263 001	Dec 20, 2002	Jan	CRLD
		FLORONE					
		@ PHARMACIA AND UPJOHN	0.05%	N17741 001		Jan	DISC
		FLORONE E					
		@ PHARMACIA AND UPJOHN	0.05%	N19259 001	Aug 28, 1985	Jan	DISC

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	+	TARO	0.05%	N75331 001	May 14, 1999	Jan	CRLD
		FLORONE					
		@ PHARMACIA AND UPJOHN	0.05%	N17994 001		Jan	DISC
		PSORCON					
		@ PHARMACIA AND UPJOHN	0.05%	N19260 001	Aug 28, 1985	Jan	DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		SANDOZ	0.25MG/ML	N40481 001	Aug 21, 2003	Jan	CAHN
----	--	--------	-----------	------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIZAC

AB4		APOTEX INC	120MG	N76395 001	Feb 01, 2006	Jan	NEWA
AB4			180MG	N76395 002	Feb 01, 2006	Jan	NEWA
AB4			240MG	N76395 003	Feb 01, 2006	Jan	NEWA
AB4			300MG	N76395 004	Feb 01, 2006	Jan	NEWA
AB4			360MG	N76395 005	Feb 01, 2006	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		AMIDE PHARM	25MG	N40542 001	Apr 21, 2006	Apr	NEWA
AB			50MG	N40542 002	Apr 21, 2006	Apr	NEWA
AB			75MG	N40542 003	Apr 21, 2006	Apr	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@ IVAX PHARMS EQ 100MG BASE

N70186 001 Nov 18, 1985 Jan DISC

@ EQ 150MG BASE

N70187 001 Nov 18, 1985 Jan DISC

@ SANDOZ EQ 100MG BASE

N70470 001 Dec 10, 1985 Jan DISC

@ EQ 150MG BASE

N70471 001 Dec 10, 1985 Jan DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ SANOFI AVENTIS US EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)

N20624 002 Sep 11, 1997 Mar CAIN



## INJECTABLE; INJECTION

## ANZEMET

+	SANOFI AVENTIS US	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624 001	Sep 11, 1997	Mar	CAIN
+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624 003	Dec 11, 2001	Mar	CAIN

## TABLET; ORAL

## ANZEMET

	SANOFI AVENTIS US	EQ 50MG BASE	N20623 001	Sep 11, 1997	Mar	CAIN
+		EQ 100MG BASE	N20623 002	Sep 11, 1997	Mar	CAIN

DOPAMINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DOPAMINE HYDROCHLORIDE

@	HOSPIRA	40MG/ML	N74403 001	May 23, 1996	Apr	DISC
@	INTL MEDICATION	40MG/ML	N18014 001		Apr	DISC
@	SICOR PHARMS	40MG/ML	N72999 001	Oct 23, 1991	Apr	DISC
@		80MG/ML	N73000 001	Oct 23, 1991	Apr	DISC

DOXYCYCLINE

## CAPSULE; ORAL

## DOXYCYCLINE

@	PAR PHARM	EQ 75MG BASE	N65055 004	Apr 18, 2005	Mar	DISC
@		EQ 150MG BASE	N65055 003	Jul 15, 2005	Mar	DISC
	RANBAXY	EQ 75MG BASE	N65053 003	Sep 10, 2003	Mar	CTEC

&gt;A&gt; CAPSULE, DELAYED RELEASE; ORAL

&gt;A&gt; ORACEA

&gt;A&gt; + COLLAGENEX PHARMS 40MG N50805 001 May 26, 2006 May NEWA

## TABLET; ORAL

## DOXYCYCLINE

>D>	PAR PHARM	EQ 75MG BASE	N65070 003	Dec 30, 2002	May	CFTG
>A>	AB	EQ 75MG BASE	N65070 003	Dec 30, 2002	May	CFTG
		EQ 75MG BASE	N65070 003	Dec 30, 2002	Mar	CMFD
>A>	AB	RANBAXY	EQ 50MG BASE	May 31, 2006	May	NEWA
>A>	AB	EQ 75MG BASE	N65356 002	May 31, 2006	May	NEWA
>A>	AB	EQ 100MG BASE	N65356 003	May 31, 2006	May	NEWA

DOXYCYCLINE HYCLATE

## CAPSULE, DELAYED RELEASE; ORAL

## DORYX

@	FH FAULDING CO LTD	EQ 75MG BASE	N50582 002	Aug 13, 2001	Apr	DISC
@		EQ 100MG BASE	N50582 001	Jul 22, 1985	Apr	DISC
@	WARNER CHILCOTT	EQ 100MG BASE	N62653 001	Oct 30, 1985	Apr	DISC

## DOXYCYCLINE HYCLATE

	SANDOZ	EQ 75MG BASE	N65281 001	Dec 21, 2005	Apr	CTEC
+		EQ 100MG BASE	N65281 002	Dec 21, 2005	Apr	CRLD

## TABLET; ORAL

## DOXYCYCLINE HYCLATE

AB PAR PHARM EQ 20MG BASE N65287 001 Feb 28, 2006 Feb NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

## TABLET; ORAL

## YAZ

+ BERLEX LABS 3MG;0.02MG N21676 001 Mar 16, 2006 Mar NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	XYLOCAINE W/ EPINEPHRINE							
	+ DENTSPLY PHARM	0.02MG/ML;2%	N21381	002			Mar	CRLD
>D>	PATCH; IONTOPHORESIS							
>D>	LIDOSITE TOPICAL SYSTEM KIT							
>D>	+ VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May		CDFR
>A>	PATCH; IONTOPHORESIS, TOPICAL							
>A>	LIDOSITE TOPICAL SYSTEM KIT							
>A>	+ VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May		CDFR
>D>	SOLUTION; IONTOPHORESIS							
>D>	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
>D>	+ EMPI	0.01MG/ML;2%	N21486	001	Oct 26, 2004	May		CDFR
>A>	SOLUTION; IONTOPHORESIS, TOPICAL							
>A>	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
>A>	+ EMPI	0.01MG/ML;2%	N21486	001	Oct 26, 2004	May		CDFR

ERYTHROMYCIN

	SOLUTION; TOPICAL							
	A/T/S							
AT	TARO PHARMS NORTH	2%	N62405	001	Nov 18, 1982	Feb		CAHN

ESCITALOPRAM OXALATE

	TABLET; ORAL							
>A>	ESCITALOPRAM OXALATE							
>A>	AB IVAX PHARMS	5MG	N76765	001	May 22, 2006	May		NEWA
>A>	AB	10MG	N76765	002	May 22, 2006	May		NEWA
>A>	AB	20MG	N76765	003	May 22, 2006	May		NEWA
	LEXAPRO							
>D>	FOREST LABS	5MG	N21323	001	Aug 14, 2002	May		CFTG
>A>	AB	5MG	N21323	001	Aug 14, 2002	May		CFTG
>D>		10MG	N21323	002	Aug 14, 2002	May		CFTG
>A>	AB	10MG	N21323	002	Aug 14, 2002	May		CFTG
>D>	+	20MG	N21323	003	Aug 14, 2002	May		CFTG
>A>	AB +	20MG	N21323	003	Aug 14, 2002	May		CFTG

ESTAZOLAM

	TABLET; ORAL							
	ESTAZOLAM							
AB	PAR PHARM	1MG	N74826	001	Jul 03, 1997	Apr		CAHN
AB		2MG	N74826	002	Jul 03, 1997	Apr		CAHN

ESTRADIOL

	GEL; TOPICAL							
	ESTROGEL							
	@ ASCEND	0.06%	N21166	001	Feb 09, 2004	Jan		CAHN
	GEL, METERED; TOPICAL							
	ESTROGEL							
	+ ASCEND	0.06%	N21166	002	Feb 09, 2004	Jan		CAHN

ESTRADIOL HEMIHYDRATE

	EMULSION; TOPICAL							
	ESTRASORB							
	+ ESPRIT PHARMA	0.25%	N21371	001	Oct 09, 2003	Feb		CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

	DURAMED	0.3MG	N21443 001	Dec 20, 2004	Mar	CMFD
		0.45MG	N21443 002	Dec 20, 2004	Mar	CMFD
		0.625MG	N21443 003	May 10, 2004	Mar	CMFD
+		1.25MG	N21443 004	May 10, 2004	Mar	CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

&gt;A&gt; TABLET; ORAL

&gt;A&gt; SEASONIQUE

>A>	+	DURAMED RES	0.03MG,0.01MG;0.15MG,N/A	N21840 001	May 25, 2006	May	NEWA
-----	---	-------------	--------------------------	------------	--------------	-----	------

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB2	WATSON LABS	0.02MG;0.1MG	N77681 001	May 31, 2006	May	NEWA
-----	-----	-------------	--------------	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

	BARR	0.035MG;0.4MG	N76198 001	Apr 22, 2004	Mar	CRLD
--	------	---------------	------------	--------------	-----	------

TABLET; ORAL-28

OVCON-35

AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		Mar	CRLD
----	---	-----------------	---------------	------------	--	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LOESTRIN 24 FE

+	WARNER CHILCOTT	0.02MG;1MG	N21871 001	Feb 17, 2006	Feb	NEWA
---	-----------------	------------	------------	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

	@	ENDO PHARMS	200MG	N74842 001	Jul 17, 1997	Feb	DISC
--	---	-------------	-------	------------	--------------	-----	------

	@		300MG	N74842 002	Jul 17, 1997	Feb	DISC
--	---	--	-------	------------	--------------	-----	------

AB	+	TARO	300MG	N75078 002	Apr 30, 1998	Mar	CRLD
----	---	------	-------	------------	--------------	-----	------

LODINE

	@	WYETH PHARMS INC	300MG	N18922 003	Jan 31, 1991	Mar	DISC
--	---	------------------	-------	------------	--------------	-----	------

TABLET; ORAL

ETODOLAC

	@	ENDO PHARMS	400MG	N74841 001	Jun 27, 1997	Feb	DISC
--	---	-------------	-------	------------	--------------	-----	------

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

	CIPHER	50MG	N21612 001	Jan 11, 2006	Jan	NEWA
--	--------	------	------------	--------------	-----	------

		100MG	N21612 002	Jan 11, 2006	Jan	NEWA
--	--	-------	------------	--------------	-----	------

+		150MG	N21612 003	Jan 11, 2006	Jan	NEWA
---	--	-------	------------	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

AB	+	TEVA	160MG	N76433 002	May 13, 2005	Jan	CRLD
----	---	------	-------	------------	--------------	-----	------

TRICOR

	@	ABBOTT	54MG	N21203 001	Sep 04, 2001	Jan	DISC
--	---	--------	------	------------	--------------	-----	------

	@		160MG	N21203 003	Sep 04, 2001	Jan	DISC
--	---	--	-------	------------	--------------	-----	------

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION  
FENOLDOPAM MESYLATE

AP SANDOZ EQ 10MG BASE/ML N77155 001 Feb 15, 2005 Jan CAHN

FENOPROFEN CALCIUM

TABLET; ORAL  
FENOPROFEN CALCIUM  
@ CLONMEL HLTHCARE

EQ 600MG BASE

N72326 001 Aug 17, 1988 Jan DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL  
ACTIQ (SUGAR-FREE)

CEPHALON EQ 0.2MG BASE  
+ EQ 0.4MG BASE  
EQ 0.6MG BASE  
EQ 0.8MG BASE  
EQ 1.2MG BASE  
EQ 1.6MG BASE

N20747 001 Nov 04, 1998 Mar CTNA  
N20747 002 Nov 04, 1998 Mar CTNA  
N20747 003 Nov 04, 1998 Mar CTNA  
N20747 004 Nov 04, 1998 Mar CTNA  
N20747 005 Nov 04, 1998 Mar CTNA  
N20747 006 Nov 04, 1998 Mar CTNA

FENTANYL HYDROCHLORIDE

>A> SYSTEM; IONTOPHORESIS, TRANSDERMAL  
>A> IONSYS  
>A> + ALZA 10.8UGM

N21338 001 May 22, 2006 May NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL  
FEXOFENADINE HYDROCHLORIDE

AB DR REDDYS LABS LTD 30MG  
AB 60MG  
AB 180MG

N76502 001 Apr 11, 2006 Mar NEWA  
N76502 002 Apr 11, 2006 Mar NEWA  
N76502 003 Apr 11, 2006 Mar NEWA

FLUCONAZOLE

TABLET; ORAL  
FLUCONAZOLE

AB GLENMARK PHARMA 50MG  
AB 100MG  
AB 150MG  
AB 200MG

N77253 001 Jan 25, 2006 Jan NEWA  
N77253 002 Jan 25, 2006 Jan NEWA  
N77253 003 Jan 25, 2006 Jan NEWA  
N77253 004 Jan 25, 2006 Jan NEWA

FLUMAZENIL

INJECTABLE; INJECTION  
FLUMAZENIL

AP SANDOZ 1MG/10ML (0.1MG/ML)  
AP 0.5MG/5ML (0.1MG/ML)

N77071 002 May 03, 2005 Jan CAHN  
N77071 001 May 03, 2005 Jan CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION  
AEROSPAN HFA

+ FOREST LABS EQ 78UGM BASE/INH

N21247 001 Jan 27, 2006 Jan NEWA

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

>A>	+	ALCON	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	May	CAHN
>D>	+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	May	CAHN
	+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	Mar	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP	+	SICOR PHARMS	50MG/ML	N40023 001	Oct 18, 1991	Mar	CRLD
			FLUOROURACIL				
AP	+	AM PHARM PARTNERS	50MG/ML	N40278 001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40279 001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40291 001	Mar 24, 1999	Mar	CRLD
AP	+		50MG/ML	N40379 001	Nov 15, 2000	Mar	CRLD
		@ BEDFORD	50MG/ML	N89508 001	Jan 26, 1988	Apr	DISC
AP	+		50MG/ML	N89508 001	Jan 26, 1988	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N40333 001	Jan 27, 2000	Mar	CRLD
AP	+		50MG/ML	N40334 001	Feb 25, 2000	Mar	CRLD
AP	+	STERIS	50MG/ML	N87792 001	Oct 13, 1982	Mar	CRLD
		@ WATSON LABS	50MG/ML	N87792 001	Oct 13, 1982	Apr	DISC

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

SARAFEM

>A>		WARNER CHILCOTT	EQ 10MG BASE	N21860 001	May 19, 2006	May	NEWA
>A>			EQ 15MG BASE	N21860 002	May 19, 2006	May	NEWA
>A>	+		EQ 20MG BASE	N21860 003	May 19, 2006	May	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

	+	PHARM ASSOC	2.5MG/5ML	N40146 001	Aug 21, 1996	Apr	CRLD
		@ TEVA PHARMS	2.5MG/5ML	N81310 001	Apr 29, 1993	Apr	DISC
		PROLIXIN					
		@ APOTHECON	2.5MG/5ML	N12145 003		Apr	DISC

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

>D>		SCHERING	125MG	N18554 001	Jan 27, 1989	May	DISC
>A>		@	125MG	N18554 001	Jan 27, 1989	May	DISC
			FLUTAMIDE				
AB		PAR PHARM	125MG	N75298 001	Sep 18, 2001	Apr	CAHN
>D>	AB	SANDOZ	125MG	N75818 001	Sep 18, 2001	May	CRLD
>A>	AB	+	125MG	N75818 001	Sep 18, 2001	May	CRLD

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		G AND W LABS	0.005%	N77168 001	Mar 03, 2006	Feb	NEWA
----	--	--------------	--------	------------	--------------	-----	------

## SPRAY, METERED; NASAL

	FLONASE								
AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG	
		FLUTICASON PROPIONATE							
AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA	

FLUVOXAMINE MALEATE

## TABLET; ORAL

		FLUVOXAMINE MALEATE							
AB		CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA	
AB			50MG	N75900	002	Feb 23, 2006	Feb	NEWA	
AB			100MG	N75900	003	Feb 23, 2006	Feb	NEWA	

FOSCARNET SODIUM

## INJECTABLE; INJECTION

		FOSCARNET SODIUM							
AP		HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN	

GABAPENTIN

## CAPSULE; ORAL

		GABAPENTIN							
AB		SANDOZ	100MG	N75428	001	Jan 24, 2006	Jan	NEWA	
AB			300MG	N75428	002	Jan 24, 2006	Jan	NEWA	
AB			400MG	N75428	003	Jan 24, 2006	Jan	NEWA	

## TABLET; ORAL

		GABAPENTIN							
AB		SANDOZ	600MG	N76120	001	Jan 27, 2006	Jan	NEWA	
AB			800MG	N76120	002	Jan 27, 2006	Jan	NEWA	

GADOVERSETAMIDE

## INJECTABLE; INJECTION

		OPTIMARK							
+		MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08, 1999	Jan	CPOT	
+			3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08, 1999	Jan	NEWA	
+			4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08, 1999	Jan	NEWA	
+			6618MG/20ML (330.9MG/ML)	N20937	004	Dec 08, 1999	Jan	NEWA	
+			16.545GM/50ML (330.9MG/ML)	N20975	001	Dec 08, 1999	Jan	CPOT	
		OPTIMARK IN PLASTIC CONTAINER							
+		MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976	001	Dec 08, 1999	Jan	CPOT	
+			3309MG/10ML (330.9MG/ML)	N20976	002	Dec 08, 1999	Jan	NEWA	
+			4963.5MG/15ML (330.9MG/ML)	N20976	003	Dec 08, 1999	Jan	NEWA	
+			6618MG/20ML (330.9MG/ML)	N20976	004	Dec 08, 1999	Jan	NEWA	

GALANTAMINE HYDROBROMIDE

## CAPSULE, EXTENDED RELEASE; ORAL

		RAZADYNE ER							
>D>	+	JANSSEN	EQ 8MG BASE	N21615	001	Dec 22, 2004	May	CMS2	
>A>	+		EQ 8MG BASE	N21615	001	Apr 01, 2005	May	CMS2	
>D>			EQ 16MG BASE	N21615	002	Dec 22, 2004	May	CMS2	
>A>			EQ 16MG BASE	N21615	002	Apr 01, 2005	May	CMS2	
>D>			EQ 24MG BASE	N21615	003	Dec 22, 2004	May	CMS2	
>A>			EQ 24MG BASE	N21615	003	Apr 01, 2005	May	CMS2	

GATIFLOXACIN

>D>	INJECTABLE; INJECTION							
>D>	TEQUIN							
>D>	+ BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	May	DISC	
>A>	@	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	May	DISC	
>D>	TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+ BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	May	DISC	
>A>	@	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	May	DISC	
>D>	+ BRISTOL MYERS SQUIBB	400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	May	DISC	
>A>	@	400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	May	DISC	
>D>	TABLET; ORAL							
>D>	TEQUIN							
>D>	BRISTOL MYERS SQUIBB	200MG	N21061	001	Dec 17, 1999	May	DISC	
>A>	@	200MG	N21061	001	Dec 17, 1999	May	DISC	
>D>	+ BRISTOL MYERS SQUIBB	400MG	N21061	002	Dec 17, 1999	May	DISC	
>A>	@	400MG	N21061	002	Dec 17, 1999	May	DISC	

GLIMEPIRIDE

	TABLET; ORAL							
	GLIMEPIRIDE							
AB	COBALT	1MG	N77280	001	Feb 03, 2006	Jan	NEWA	
AB		2MG	N77280	002	Feb 03, 2006	Jan	NEWA	
AB		4MG	N77280	003	Feb 03, 2006	Jan	NEWA	
AB	GENPHARM	1MG	N77486	001	Feb 10, 2006	Jan	NEWA	
AB		2MG	N77486	002	Feb 10, 2006	Jan	NEWA	
AB		4MG	N77486	003	Feb 10, 2006	Jan	NEWA	

GLIPIZIDE

	TABLET; ORAL							
	GLIPIZIDE							
	@ ENDO PHARMS	5MG	N74378	001	Nov 28, 1994	Feb	DISC	
	@	10MG	N74378	002	Nov 28, 1994	Feb	DISC	
	TABLET, EXTENDED RELEASE; ORAL							
	GLIPIZIDE							
AB	WATSON LABS	2.5MG	N76467	003	Mar 27, 2006	Mar	NEWA	
AB	GLUCOTROL XL							
AB	PFIZER	2.5MG	N20329	003	Aug 10, 1999	Mar	CFTG	

GLYBURIDE

	TABLET; ORAL							
	DIABETA							
BX	+ SANOFI AVENTIS US	5MG	N17532	003	May 01, 1984	Feb	CRLD	

GUANFACINE HYDROCHLORIDE

	TABLET; ORAL							
	TENEX							
>A>	AB DR REDDYS LABS INC	EQ 1MG BASE	N19032	001	Oct 27, 1986	May	CAHN	
>A>	AB +	EQ 2MG BASE	N19032	002	Nov 07, 1988	May	CAHN	
>A>	@	EQ 3MG BASE	N19032	003	Nov 07, 1988	May	CAHN	
>D>	AB ESP PHARMA	EQ 1MG BASE	N19032	001	Oct 27, 1986	May	CAHN	
>D>	AB +	EQ 2MG BASE	N19032	002	Nov 07, 1988	May	CAHN	
>D>	@	EQ 3MG BASE	N19032	003	Nov 07, 1988	May	CAHN	

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	N77123 001	Dec 16, 2004	Apr	CAHN
----	----------------	-------	------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	PERRIGO	0.05%	N76872 001	Dec 16, 2004	Mar	CAHN
----	---------	-------	------------	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	SANDOZ	EQ 50MG BASE/ML	N76463 001	Jun 24, 2005	Jan	CAHN
----	--------	-----------------	------------	--------------	-----	------

AO		EQ 100MG BASE/ML	N76463 002	Jun 24, 2005	Jan	CAHN
----	--	------------------	------------	--------------	-----	------

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	SANDOZ	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Jan	CAHN
----	--------	----------------	------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

APRESOLINE

@ NOVARTIS

10MG

N08303 004

Feb DISC

@

25MG

N08303 001

Feb DISC

@

50MG

N08303 002

Feb DISC

@

100MG

N08303 005

Feb DISC

HYDRALAZINE HYDROCHLORIDE

>D>	@ ABC HOLDING	10MG	N88846 001	Feb 26, 1985	May	CAHN
-----	---------------	------	------------	--------------	-----	------

>D>	@	25MG	N88847 001	Feb 26, 1985	May	CAHN
-----	---	------	------------	--------------	-----	------

>D>	@	50MG	N88848 001	Feb 26, 1985	May	CAHN
-----	---	------	------------	--------------	-----	------

>D>	@	100MG	N88849 001	Feb 26, 1985	May	CAHN
-----	---	-------	------------	--------------	-----	------

AA	+	PLIVA	10MG	N89097 001	Dec 18, 1985	Feb	CRLD
----	---	-------	------	------------	--------------	-----	------

AA	+		25MG	N88467 001	May 01, 1984	Feb	CRLD
----	---	--	------	------------	--------------	-----	------

AA	+		50MG	N88468 001	May 01, 1984	Feb	CRLD
----	---	--	------	------------	--------------	-----	------

AA	+		100MG	N89098 001	Dec 18, 1985	Feb	CRLD
----	---	--	-------	------------	--------------	-----	------

>A>	@	TG UNITED LABS	10MG	N88846 001	Feb 26, 1985	May	CAHN
-----	---	----------------	------	------------	--------------	-----	------

>A>	@		25MG	N88847 001	Feb 26, 1985	May	CAHN
-----	---	--	------	------------	--------------	-----	------

>A>	@		50MG	N88848 001	Feb 26, 1985	May	CAHN
-----	---	--	------	------------	--------------	-----	------

>A>	@		100MG	N88849 001	Feb 26, 1985	May	CAHN
-----	---	--	-------	------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

>D>	@	ABC HOLDING	25MG;15MG;0.1MG	N84897 001		May	CAHN
-----	---	-------------	-----------------	------------	--	-----	------

>A>	@	TG UNITED LABS	25MG;15MG;0.1MG	N84897 001		May	CAHN
-----	---	----------------	-----------------	------------	--	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	@	ABC HOLDING	25MG	N85683 001		May	CAHN
-----	---	-------------	------	------------	--	-----	------

>D>	@		50MG	N83965 001		May	CAHN
-----	---	--	------	------------	--	-----	------

>A>	@	TG UNITED LABS	25MG	N85683 001		May	CAHN
-----	---	----------------	------	------------	--	-----	------

>A>	@		50MG	N83965 001		May	CAHN
-----	---	--	------	------------	--	-----	------



HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO	12.5MG;10MG	N77606 001	Mar 14, 2006	Feb	NEWA
AB		12.5MG;20MG	N77606 002	Mar 14, 2006	Feb	NEWA
AB		25MG;20MG	N77606 003	Mar 14, 2006	Feb	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS

		12.5MG;320MG	N20818 004	Apr 28, 2006	Apr	NEWA
		25MG;160MG	N20818 003	Jan 17, 2002	Apr	CRLD
+		25MG;320MG	N20818 005	Apr 28, 2006	Apr	NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

HOSPIRA

AP		EQ 100MG BASE/VIAL	N40666 001	Apr 06, 2006	Mar	NEWA
----	--	--------------------	------------	--------------	-----	------

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

PHARMAFORCE

AT		1%;EQ 3.5MG BASE;10,000 UNITS	N65219 001	May 01, 2006	Apr	NEWA
----	--	-------------------------------	------------	--------------	-----	------

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

BARR

VISTARIL

@ PFIZER

		EQ 100MG HCL	N88488 001	Jun 15, 1984	Mar	CTEC
		EQ 100MG HCL	N11459 006		Mar	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE

		EQ 3MG BASE/3ML	N21858 001	Jan 06, 2006	Jan	NEWA
--	--	-----------------	------------	--------------	-----	------

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ FARMACON IL

		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903 001	Apr 13, 2006	Apr	NEWA
--	--	------------------------------------	------------	--------------	-----	------

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOMETHACIN

+ G AND W LABS

		50MG	N73314 001	Aug 31, 1992	Apr	CTNA
--	--	------	------------	--------------	-----	------

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US

		1000 UNITS/10ML (100 UNITS/ML)	N21629 001	Apr 16, 2004	Mar	CMFD
--	--	--------------------------------	------------	--------------	-----	------

+		300 UNITS/3ML (100 UNITS/ML)	N21629 002	Dec 20, 2005	Mar	CMFD
---	--	------------------------------	------------	--------------	-----	------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

EXUBERA

		PFIZER	1MG/INH	N21868	001	Jan 27, 2006	Jan	NEWA
	+		3MG/INH	N21868	002	Jan 27, 2006	Jan	NEWA

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

>D>		ATROVENT						
>D>	+	BOEHRINGER INGELHEIM	0.018MG/INH	N19085	001	Dec 29, 1986	May	DISC
>A>	@		0.018MG/INH	N19085	001	Dec 29, 1986	May	DISC

SOLUTION; INHALATION

>D>		ATROVENT						
>D>	AN	+	BOEHRINGER INGELHEIM	0.02%	N20228	001	Sep 29, 1993	May
>A>	@			0.02%	N20228	001	Sep 29, 1993	May
		IPRATROPIUM BROMIDE						
>D>	AN	DEY	0.02%	N74755	001	Jan 10, 1997	May	CRLD
>A>	AN	+		0.02%	N74755	001	Jan 10, 1997	May
>D>	AN	ROXANE	0.02%	N75867	001	Jul 22, 2002	May	DISC
>A>	@			0.02%	N75867	001	Jul 22, 2002	May

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP		SANDOZ	100MG/ML	N40648	001	Jul 05, 2005	Jan	CAHN
----	--	--------	----------	--------	-----	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

>A>	AB	DR REDDYS LABS INC	20MG	N19091	001	Dec 30, 1991	May	CAHN
>D>	AB	ESP PHARMA	20MG	N19091	001	Dec 30, 1991	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

	AB	WEST WARD	30MG	N76813	002	Mar 30, 2006	Mar	NEWA
--	----	-----------	------	--------	-----	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL

CLARAVIS

>A>	AB	BARR	30MG	N76135	003	May 11, 2006	May	NEWA
-----	----	------	------	--------	-----	--------------	-----	------

SOTRET

>D>		RANBAXY	30MG	N76503	001	Jun 20, 2003	May	CTEC
>A>	AB		30MG	N76503	001	Jun 20, 2003	May	CTEC

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

>D>		DYNACIRC						
>D>	AB	+	RELIANT PHARMS	2.5MG	N19546	001	Dec 20, 1990	May
>A>	@			2.5MG	N19546	001	Dec 20, 1990	May

ISRADIPINE

	AB	ABRIKA PHARMS	5MG	N77317	002	Jan 05, 2006	Apr	CTEC
	AB	AMIDE PHARM	2.5MG	N77169	001	Apr 24, 2006	Apr	NEWA
	AB		5MG	N77169	002	Apr 24, 2006	Apr	NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION  
KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271 001	Oct 06, 2004	Jan	CAHN
AP		30MG/ML	N76271 002	Oct 06, 2004	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC  
KETOTIFEN FUMARATE

AT	APOTEX	EQ 0.025% BASE	N77354 001	May 09, 2006	Apr	NEWA
AT	+ ZADITOR					
AT	+ NOVARTIS	EQ 0.025% BASE	N21066 001	Jul 02, 1999	Apr	CFTG

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAP PHARM	15MG,N/A;N/A,250MG	N21507 002	Nov 14, 2003	Feb	CTNA
-----------	--------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAP PHARM	15MG,N/A;N/A,375MG	N21507 003	Nov 14, 2003	Feb	CTNA
-----------	--------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 500 (COPACKAGED)

+ TAP PHARM	15MG,N/A;N/A,500MG	N21507 004	Nov 14, 2003	Feb	CTNA
-------------	--------------------	------------	--------------	-----	------

LEVETIRACETAM

TABLET; ORAL

KEPPRA

UCB INC	750MG	N21035 003	Nov 30, 1999	Mar	CRLD
---------	-------	------------	--------------	-----	------

+	1GM	N21035 004	Jan 06, 2006	Mar	NEWA
---	-----	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON	EQ 0.5% BASE	N21114 001	Feb 23, 2000	Feb	CAHN
---------	--------------	------------	--------------	-----	------

>D> LEVOCABASTINE HYDROCHLORIDE

>D> SUSPENSION/DROPS; OPHTHALMIC

>D> LIVOSTIN

>D> + NOVARTIS	EQ 0.05% BASE	N20219 001	Nov 10, 1993	May	DISC
----------------	---------------	------------	--------------	-----	------

>A> @	EQ 0.05% BASE	N20219 001	Nov 10, 1993	May	DISC
-------	---------------	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

AT + POLYMEDICA	2%	N80429 001		Jan	CDFR
-----------------	----	------------	--	-----	------

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

+ ENDO PHARMS	70MG;70MG	N21623 001	Jun 23, 2005	Feb	CAHN
---------------	-----------	------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB AUROBINDO	2.5MG	N77622 001	Feb 22, 2006	Feb	NEWA
--------------	-------	------------	--------------	-----	------

AB	5MG	N77622 002	Feb 22, 2006	Feb	NEWA
----	-----	------------	--------------	-----	------

TABLET; ORALLISINOPRIL

AB	AUROBINDO	10MG	N77622 003	Feb 22, 2006	Feb	NEWA
AB		20MG	N77622 004	Feb 22, 2006	Feb	NEWA
AB		30MG	N77622 005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622 006	Feb 22, 2006	Feb	NEWA

LORAZEPAMTABLET; ORALLORAZEPAM

AB	MYLAN	0.5MG	N77657 001	Mar 16, 2006	Mar	NEWA
AB		1MG	N77657 002	Mar 16, 2006	Mar	NEWA
AB		2MG	N77657 003	Mar 16, 2006	Mar	NEWA
AB	VINTAGE PHARMS	0.5MG	N77754 001	May 10, 2006	Apr	NEWA
AB		1MG	N77754 002	May 10, 2006	Apr	NEWA
AB		2MG	N77754 003	May 10, 2006	Apr	NEWA

LOVASTATINTABLET; ORALLOVASTATIN

AB	MUTUAL PHARM	10MG	N77520 001	Apr 14, 2006	Apr	NEWA
AB		20MG	N77520 002	Apr 14, 2006	Apr	NEWA
AB		40MG	N77520 003	Apr 14, 2006	Apr	NEWA

LOVASTATIN; NIACINTABLET, EXTENDED RELEASE; ORALADVICOR

+	KOS LIFE	20MG;750MG	N21249 002	Dec 17, 2001	Feb	CMFD
---	----------	------------	------------	--------------	-----	------

LUBIPROSTONECAPSULE; ORALAMITIZA

+	SUCAMPO PHARMS	24UGM	N21908 001	Jan 31, 2006	Jan	NEWA
---	----------------	-------	------------	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATETABLET, CHEWABLE; ORALZEGERID

	SANTARUS	700MG;20MG;600MG	N21850 001	Mar 24, 2006	Mar	NEWA
+		700MG;40MG;600MG	N21850 002	Mar 24, 2006	Mar	NEWA

MEDROXYPROGESTERONE ACETATEINJECTABLE; SUBCUTANEOUSDEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N21583 001	Dec 17, 2004	Jan	CAHN
---	----------------------	--------------	------------	--------------	-----	------

MEGESTROL ACETATESUSPENSION; ORALMEGESTROL ACETATE

AB	APOTEX	40MG/ML	N77404 001	Feb 16, 2006	Jan	NEWA
----	--------	---------	------------	--------------	-----	------

MEPROBAMATETABLET; ORALMEPROBAMATE

	@ ROXANE	600MG	N84332 001		Jan	DISC
	@ SANDOZ	200MG	N14547 002		Jan	DISC

## TABLET; ORAL

		MEPROBAMATE						
		@ SANDOZ	400MG	N14547	001		Jan	DISC
		@	400MG	N80655	001		Jan	DISC
		@ SCHERER LABS	400MG	N83343	001		Jan	DISC
		@ TABLICAPS	400MG	N83494	001		Jan	DISC
AA	+	WATSON LABS	200MG	N83304	001		Jan	CRLD
		@	200MG	N85720	001		Jan	DISC
	+		400MG	N83308	001		Jan	CRLD
		@	400MG	N85721	001		Jan	DISC
		MILTOWN						
		@ MEDPOINTE PHARM HLC	200MG	N09698	004		Jan	DISC
		@	400MG	N09698	002		Jan	DISC
		TRANMEP						
		@ SOLVAY	400MG	N16249	001		Jan	DISC

MESALAMINE

## ENEMA; RECTAL

		ROWASA						
AB	+	ALAVEN PHARM	4GM/60ML	N19618	001	Dec 24, 1987	Apr	CAHN

## SUPPOSITORY; RECTAL

		CANASA						
>D>		AXCAN SCANDIPHARM	500MG	N21252	001	Jan 05, 2001	May	DISC
>A>		@	500MG	N21252	001	Jan 05, 2001	May	DISC

METFORMIN HYDROCHLORIDE

## TABLET; ORAL

		METFORMIN HYDROCHLORIDE						
>A>	AB	INTERPHARM	500MG	N77880	001	Jun 05, 2006	May	NEWA
>A>	AB		850MG	N77880	002	Jun 05, 2006	May	NEWA
>A>	AB		1GM	N77880	003	Jun 05, 2006	May	NEWA

## TABLET, EXTENDED RELEASE; ORAL

## GLUMETZA

BX		DEPOMED INC	500MG	N21748	001	Jun 03, 2005	Jan	CAHN
BX			1GM	N21748	002	Jun 03, 2005	Jan	CAHN

## METFORMIN HYDROCHLORIDE

AB		SUN PHARM INDS (IN)	500MG	N77336	001	Feb 09, 2006	Jan	NEWA
AB			750MG	N77336	002	Feb 09, 2006	Jan	NEWA

METHIMAZOLE

## TABLET; ORAL

## METHIMAZOLE

>D>		CEDAR PHARMS	20MG	N40547	004	Feb 18, 2005	May	CRLD
>A>	+		20MG	N40547	004	Feb 18, 2005	May	CRLD
>D>	AB	JONES PHARMA	5MG	N40320	001	Mar 31, 2000	May	CTNA
>D>	AB		10MG	N40320	002	Mar 31, 2000	May	CTNA
>A>		TAPAZOLE						
>A>	AB	JONES PHARMA	5MG	N40320	001	Mar 31, 2000	May	CTNA
>A>	AB		10MG	N40320	002	Mar 31, 2000	May	CTNA

METHOTREXATE SODIUM

## INJECTABLE; INJECTION

## METHOTREXATE PRESERVATIVE FREE

+		BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Apr	CAIN
+		MAYNE PHARMA USA	EQ 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	CPOT

INJECTABLE; INJECTIONMETHOTREXATE SODIUM

AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340 001	Sep 16, 1986	Apr	CPOT
	+		EQ 100MG BASE/4ML (25 MG/ML)	N89341 001	Sep 16, 1986	Apr	CTEC
	+		EQ 200MG BASE/8ML (25 MG/ML)	N89342 001	Sep 16, 1986	Apr	CTEC
	+		EQ 250MG BASE/10ML (25 MG/ML)	N89343 001	Sep 16, 1986	Apr	CTEC

METHYLPHENIDATE

## FILM, EXTENDED RELEASE; TRANSDERMAL

## DAYTRANA

	+	SHIRE	10MG/9HR (1.1MG/HR)	N21514 001	Apr 06, 2006	Apr	NEWA
	+		15MG/9HR (1.6MG/HR)	N21514 002	Apr 06, 2006	Apr	NEWA
	+		20MG/9HR (2.2MG/HR)	N21514 003	Apr 06, 2006	Apr	NEWA
	+		30MG/9HR (3.3MG/HR)	N21514 004	Apr 06, 2006	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## METADATE CD

BX		UCB INC	40MG	N21259 004	Feb 19, 2006	Feb	NEWA
			50MG	N21259 005	Feb 19, 2006	Feb	NEWA
	+		60MG	N21259 006	Feb 19, 2006	Feb	NEWA
		RITALIN LA					
BX	+	NOVARTIS	40MG	N21284 003	Jun 05, 2002	Feb	CTEC

METOCLOPRAMIDE HYDROCHLORIDE

## TABLET; ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

AB		MUTUAL PHARM	EQ 5MG BASE	N71536 002	Jan 16, 1997	Apr	CMFD
AB			EQ 10MG BASE	N71536 001	Apr 28, 1993	Apr	CMFD

## TABLET, ORALLY DISINTEGRATING; ORAL

>D>		REGLAN ODT					
>D>		SCHWARZ PHARMA	EQ 5MG BASE	N21793 001	Jun 10, 2005	May	DISC
>A>		@	EQ 5MG BASE	N21793 001	Jun 10, 2005	May	DISC
>D>	+		EQ 10MG BASE	N21793 002	Jun 10, 2005	May	DISC
>A>		@	EQ 10MG BASE	N21793 002	Jun 10, 2005	May	DISC

METRONIDAZOLE

## GEL; TOPICAL

## METROGEL

>D>	+	GALDERMA LABS LP	0.75%	N19737 001	Nov 22, 1988	May	CFTG
>A>	AB	+	0.75%	N19737 001	Nov 22, 1988	May	CFTG
>A>		METRONIDAZOLE					
>A>	AB	ALTANA	0.75%	N77018 001	Jun 06, 2006	May	NEWA

## LOTION; TOPICAL

## METROLOTION

>D>	+	GALDERMA LABS LP	0.75%	N20901 001	Nov 24, 1998	May	CFTG
>A>	AB	+	0.75%	N20901 001	Nov 24, 1998	May	CFTG
>A>		METRONIDAZOLE					
>A>	AB	ALTANA	0.75%	N77197 001	May 24, 2006	May	NEWA

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

## OINTMENT; TOPICAL

## VUSION

	+	BARRIER	0.25%;81.35%;15%	N21026 001	Feb 16, 2006	Feb	NEWA
--	---	---------	------------------	------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION  
MIDAZOLAM HYDROCHLORIDE

AP + HOSPIRA EQ 5MG BASE/ML N75293 002 Jun 20, 2000 Mar CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL  
MINOCIN

AB TRIAX PHARMS EQ 50MG BASE N50649 001 May 31, 1990 Feb CAHN

@ EQ 75MG BASE N50649 003 Feb 12, 2001 Feb CAHN

AB + EQ 100MG BASE N50649 002 May 31, 1990 Feb CAHN

>A> TABLET, EXTENDED RELEASE; ORAL

>A> SOLODYN

>A> MEDICIS EQ 45MG BASE N50808 001 May 08, 2006 May NEWA

>A> EQ 90MG BASE N50808 002 May 08, 2006 May NEWA

>A> + EQ 135MG BASE N50808 003 May 08, 2006 May NEWA

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL  
MIRTAZAPINE

AB AUROBINDO PHARMA LTD 45MG N77376 004 Feb 28, 2006 Feb NEWA

AB BARR 45MG N76307 003 Feb 28, 2006 Feb NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION  
MITOXANTRONE

AP AM PHARM EQ 20MG BASE/10ML (2MG/ML) N77496 001 Apr 11, 2006 Mar NEWA

AP EQ 25MG BASE/12.5ML (2MG/ML) N77496 002 Apr 11, 2006 Mar NEWA

AP EQ 30MG BASE/15ML (2MG/ML) N77496 003 Apr 11, 2006 Mar NEWA

AP BEDFORD EQ 20MG BASE/10ML (2MG/ML) N76611 001 Apr 11, 2006 Mar NEWA

AP EQ 25MG BASE/12.5ML (2MG/ML) N76611 002 Apr 11, 2006 Mar NEWA

AP EQ 30MG BASE/15ML (2MG/ML) N76611 003 Apr 11, 2006 Mar NEWA

AP MAYNE PHARMA USA EQ 20MG BASE/10ML (2MG/ML) N76871 001 Apr 11, 2006 Mar NEWA

AP EQ 25MG BASE/12.5ML (2MG/ML) N76871 002 Apr 11, 2006 Mar NEWA

AP EQ 30MG BASE/15ML (2MG/ML) N76871 003 Apr 11, 2006 Mar NEWA

AP SICOR PHARMS EQ 20MG BASE/10ML (2MG/ML) N77356 001 Apr 11, 2006 Mar NEWA

AP EQ 25MG BASE/12.5ML (2MG/ML) N77356 002 Apr 11, 2006 Mar NEWA

AP EQ 30MG BASE/15ML (2MG/ML) N77356 003 Apr 11, 2006 Mar NEWA

NOVANTRONE

AP + SERONO INC EQ 20MG BASE/10ML (2MG/ML) N19297 001 Dec 23, 1987 Mar CFTG

AP + EQ 25MG BASE/12.5ML (2MG/ML) N19297 002 Dec 23, 1987 Mar CFTG

AP + EQ 30MG BASE/15ML (2MG/ML) N19297 003 Dec 23, 1987 Mar CFTG

MOMETASONE FUROATE

CREAM; TOPICAL  
MOMETASONE FUROATE

>A> AB G AND W LABS 0.1% N77447 001 May 22, 2006 May NEWA

LOTION; TOPICAL

MOMETASONE FUROATE

AB PERRIGO 0.1% N77180 001 Apr 06, 2005 Mar CAHN

AB TARO 0.1% N76788 001 Mar 15, 2006 Feb NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA

5MG/ML

N19916 002 Mar 30, 2006 Mar NEWA

NABILONE

CAPSULE; ORAL

CESAMET

&gt;D&gt; @ VALEANT

1MG

N18677 001 Dec 26, 1985 May CMFD

&gt;A&gt; +

1MG

N18677 001 Dec 26, 1985 May CMFD

NABUMETONE

TABLET; ORAL

NABUMETONE

AB PAR PHARM

500MG

N76009 001 Jan 24, 2003 Apr CAHN

AB

750MG

N76009 002 Jan 24, 2003 Apr CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP + SANDOZ

EQ 1GM BASE/VIAL

N62527 002 Aug 02, 1984 Apr CRLD

AP +

EQ 1GM BASE/VIAL

N62732 001 Dec 23, 1986 Apr CRLD

AP +

EQ 2GM BASE/VIAL

N62527 003 Aug 02, 1984 Apr CRLD

AP +

EQ 2GM BASE/VIAL

N62732 002 Dec 23, 1986 Apr CRLD

AP +

EQ 10GM BASE/VIAL

N62527 004 Aug 02, 1984 Apr CRLD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+ ALKERMES

380MG/VIAL

N21897 001 Apr 13, 2006 Apr NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN AND POLYMYXIN B SULFATE

AT X GEN PHARMS

EQ 40MG BASE/ML;200,000 UNITS/ML

N65106 001 Jan 31, 2006 Jan NEWA

AT

EQ 800MG BASE/20ML;4,000,000

N65108 001 Jan 31, 2006 Jan NEWA

UNITS/20ML (EQ 40MG  
BASE/ML;200,000 UNITS/ML)

NEOSPORIN G.U. IRRIGANT

AT + MONARCH PHARMS

EQ 40MG BASE/ML;200,000 UNITS/ML

N60707 001

Jan CTEC

AT +

EQ 800MG BASE/20ML;4,000,000

N60707 002

Jan NEWA

UNITS/20ML (EQ 40MG  
BASE/ML;200,000 UNITS/ML)NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB BARR

20MG

N74439 001 Dec 10, 1996 Apr CAHN

AB

30MG

N74439 002 Dec 10, 1996 Apr CAHN

INJECTABLE; INJECTION

CARDENE

+ PDL BIOPHARMA INC

2.5MG/ML

N19734 001 Jan 30, 1992 Jan CAHN



NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

AB1	WATSON LABS	30MG	N75128 001	Mar 10, 2000	Jan	CAHN
AB1		60MG	N75659 001	Oct 26, 2001	Jan	CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>A>	AP	METRICS PHARM	EQ 1MG BASE/ML	N40522 001	Sep 30, 2004	May	CAHN
>D>	AP	PHARMAFORCE	EQ 1MG BASE/ML	N40522 001	Sep 30, 2004	May	CAHN

NYSTATIN

CREAM; TOPICAL

NYSTATIN

>D>	AT	TARO	100,000 UNITS/GM	N62457 001	Jul 28, 1983	May	DISC
>A>		@	100,000 UNITS/GM	N62457 001	Jul 28, 1983	May	DISC
>A>	AT	VINTAGE	100,000 UNITS/GM	N65315 001	May 31, 2006	May	NEWA

SUSPENSION; ORAL

NYSTATIN

>D>		@ TARO	100,000 UNITS/ML	N62876 001	Feb 29, 1988	May	CMFD
>A>	AA		100,000 UNITS/ML	N62876 001	Feb 29, 1988	May	CMFD

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	AM PHARM	EQ 0.2MG BASE/ML	N77450 001	Feb 10, 2006	Jan	NEWA
AP		EQ 1MG BASE/ML	N77450 002	Feb 10, 2006	Jan	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM	EQ 0.05MG BASE/ML	N77457 001	Feb 10, 2006	Jan	NEWA
AP		EQ 0.1MG BASE/ML	N77457 002	Feb 10, 2006	Jan	NEWA
AP		EQ 0.5MG BASE/ML	N77457 003	Feb 10, 2006	Jan	NEWA

OFLOXACIN

TABLET; ORAL

OFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098 001	Feb 10, 2006	Jan	NEWA
AB		300MG	N77098 002	Feb 10, 2006	Jan	NEWA
AB		400MG	N77098 003	Feb 10, 2006	Jan	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

SANTARUS 20MG;1.1GM

N21849 001 Feb 27, 2006 Feb NEWA

+ 40MG;1.1GM

N21849 002 Feb 27, 2006 Feb NEWA

FOR SUSPENSION; ORAL

ZEGERID

SANTARUS 20MG/PACKET;1.68GM/PACKET

N21636 001 Jun 15, 2004 Feb CAIN

+ 40MG/PACKET;1.68GM/PACKET

N21706 001 Dec 21, 2004 Feb CAIN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

>A>	AP	AKORN	30MG/ML	N40484 001	May 24, 2006	May	NEWA
-----	----	-------	---------	------------	--------------	-----	------

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+	ALAVEN PHARM	50MG	N16848 001		Apr	CAHN
---	--------------	------	------------	--	-----	------

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+	ABRAXIS BIOSCIENCE	100MG/VIAL	N21660 001	Jan 07, 2005	Apr	CAHN
---	--------------------	------------	------------	--------------	-----	------

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

JDS PHARMS

		EQ 10MG BASE	N21299 001	Jul 03, 2003	Apr	CAHN
		EQ 20MG BASE	N21299 002	Jul 03, 2003	Apr	CAHN
		EQ 30MG BASE	N21299 003	Jul 03, 2003	Apr	CAHN
+		EQ 40MG BASE	N21299 004	Jul 03, 2003	Apr	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

>D>	+	EYETECH PHARMS	EQ 0.3MG ACID/0.09ML	N21756 001	Dec 17, 2004	May	CAHN
>A>	+	OSI EYETECH	EQ 0.3MG ACID/0.09ML	N21756 001	Dec 17, 2004	May	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

AA		AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529 001		Jan	CAHN
AA			EQ 250MG BASE/5ML	N61529 002		Jan	CAHN

TABLET; ORAL

PENICILLIN V POTASSIUM

@ AM ANTIBIOTICS

@

			EQ 250MG BASE	N61528 001		Jan	CAHN
			EQ 500MG BASE	N61528 002		Jan	CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

AB		PAR PHARM	EQ 0.05MG BASE	N76061 001	Nov 27, 2002	Apr	CAHN
AB			EQ 0.25MG BASE	N76061 002	Nov 27, 2002	Apr	CAHN
AB			EQ 1MG BASE	N76061 003	Nov 27, 2002	Apr	CAHN
		PERMAX					
AB		VALEANT	EQ 0.05MG BASE	N19385 001	Dec 30, 1988	Jan	CRLD
AB	+		EQ 0.25MG BASE	N19385 002	Dec 30, 1988	Jan	CRLD

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

CAM-METRAZINE

>D>		@ ABC HOLDING	35MG	N83922 001		May	CAHN
>D>		@	35MG	N85318 001		May	CAHN
>D>		@	35MG	N85320 001		May	CAHN
>D>		@	35MG	N85321 001		May	CAHN
>A>		@ TG UNITED LABS	35MG	N83922 001		May	CAHN
>A>		@	35MG	N85318 001		May	CAHN
>A>		@	35MG	N85320 001		May	CAHN

## TABLET; ORAL

CAM-METRAZINE					
>A>	@ TG UNITED LABS	35MG	N85321 001	May	CAHN
PHENDIMETRAZINE TARTRATE					
>D>	@ ABC HOLDING	35MG	N85761 001	May	CAHN
>D>	@	35MG	N85941 001	Jun 27, 1983	May CAHN
>A>	@ TG UNITED LABS	35MG	N85761 001	May	CAHN
>A>	@	35MG	N85941 001	Jun 27, 1983	May CAHN

PHENTERMINE HYDROCHLORIDE

## CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE					
>D>	@ ABC HOLDING	18.75MG	N88576 001	May 23, 1984	May CAHN
>D>	@	30MG	N85417 001		May CAHN
>D>	@	30MG	N86732 002		May CAHN
>D>	@	30MG	N87215 001		May CAHN
>D>	@	37.5MG	N87915 001	Dec 22, 1983	May CAHN
>D>	@	37.5MG	N87918 001	Dec 22, 1983	May CAHN
>D>	@	37.5MG	N87930 001	Oct 14, 1983	May CAHN
>D>	@	37.5MG	N88610 001	Jun 04, 1984	May CAHN
>D>	@	37.5MG	N88611 001	Jun 04, 1984	May CAHN
>D>	@	37.5MG	N88625 001	Aug 23, 1984	May CAHN
>A>	@ TG UNITED LABS	18.75MG	N88576 001	May 23, 1984	May CAHN
>A>	@	30MG	N85417 001		May CAHN
>A>	@	30MG	N86732 002		May CAHN
>A>	@	30MG	N87215 001		May CAHN
>A>	@	37.5MG	N87915 001	Dec 22, 1983	May CAHN
>A>	@	37.5MG	N87918 001	Dec 22, 1983	May CAHN
>A>	@	37.5MG	N87930 001	Oct 14, 1983	May CAHN
>A>	@	37.5MG	N88610 001	Jun 04, 1984	May CAHN
>A>	@	37.5MG	N88611 001	Jun 04, 1984	May CAHN
>A>	@	37.5MG	N88625 001	Aug 23, 1984	May CAHN

## TABLET; ORAL

PHENTERMINE HYDROCHLORIDE					
>D>	@ ABC HOLDING	8MG	N83923 001		May CAHN
>D>	@	8MG	N85319 001		May CAHN
>D>	@	37.5MG	N87805 001	Dec 06, 1982	May CAHN
>D>	@	37.5MG	N88596 001	Apr 04, 1984	May CAHN
>A>	@ TG UNITED LABS	8MG	N83923 001		May CAHN
>A>	@	8MG	N85319 001		May CAHN
>A>	@	37.5MG	N87805 001	Dec 06, 1982	May CAHN
>A>	@	37.5MG	N88596 001	Apr 04, 1984	May CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

## SYRUP; ORAL

## PROMETH VC PLAIN

+	ALPHARMA US PHARMS	5MG/5ML; 6.25MG/5ML	N88761 001	Nov 08, 1984	Jan CTEC
---	--------------------	---------------------	------------	--------------	----------

## PROMETHAZINE VC PLAIN

	@ MORTON GROVE	5MG/5ML; 6.25MG/5ML	N88897 001	Jan 04, 1985	Jan DISC
--	----------------	---------------------	------------	--------------	----------

PHYTONADIONE

## INJECTABLE; INJECTION

## AQUAMEPHYTON

	@ MERCK	1MG/0.5ML	N12223 002		Feb DISC
	@	10MG/ML	N12223 001		Feb DISC

## INJECTABLE; INJECTION

## VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	Feb	CRLD
	+		10MG/ML	N87955	001	Jul 25, 1983	Feb	CRLD

PILOCARPINE HYDROCHLORIDE

## TABLET; ORAL

## PILOCARPINE HYDROCHLORIDE

AB		IMPAX LABS	5MG	N77248	001	Mar 31, 2006	Mar	NEWA
AB			7.5MG	N77248	002	Mar 31, 2006	Mar	NEWA
		SALAGEN						
AB	+	MGI PHARMA INC	7.5MG	N20237	002	Apr 18, 2003	Mar	CFTG

POLYETHYLENE GLYCOL 3350

## FOR SOLUTION; ORAL

## POLYETHYLENE GLYCOL 3350

>A>	AA	COASTAL PHARMS	17GM/SCOOPFUL	N77893	001	May 26, 2006	May	NEWA
>A>	AA	KALI LABS	17GM/SCOOPFUL	N77736	001	May 26, 2006	May	NEWA
	AA	TEVA PHARMS	17GM/SCOOPFUL	N77445	001	May 04, 2006	Apr	NEWA

POTASSIUM CHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## KLOR-CON

AB		UPSHER SMITH	8MEQ	N19123	001	Apr 17, 1986	Jan	CRLD
		POTASSIUM CHLORIDE						
AB	+	COPLLEY PHARM	8MEQ	N70618	001	Sep 09, 1987	Jan	CRLD

POTASSIUM CITRATE

## TABLET, EXTENDED RELEASE; ORAL

## POTASSIUM CITRATE

>A>	AB	COREPHARMA	5MEQ	N77440	001	Jun 09, 2006	May	NEWA
>A>	AB		10MEQ	N77440	002	Jun 09, 2006	May	NEWA
		UROCIT-K						
>D>		MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	May	CFTG
>A>	AB		5MEQ	N19071	001	Aug 30, 1985	May	CFTG
>D>		+	10MEQ	N19071	002	Aug 31, 1992	May	CFTG
>A>	AB	+	10MEQ	N19071	002	Aug 31, 1992	May	CFTG

PRAVASTATIN SODIUM

## TABLET; ORAL

## PRAVACHOL

AB		BRISTOL MYERS SQUIBB	10MG	N19898	002	Oct 31, 1991	Apr	CFTG
AB			20MG	N19898	003	Oct 31, 1991	Apr	CFTG
AB			40MG	N19898	004	Mar 22, 1993	Apr	CFTG
		PRAVASTATIN SODIUM						
AB		TEVA	10MG	N76056	001	Apr 24, 2006	Apr	NEWA
AB			20MG	N76056	002	Apr 24, 2006	Apr	NEWA
AB			40MG	N76056	003	Apr 24, 2006	Apr	NEWA

PRAZOSIN HYDROCHLORIDE

## CAPSULE; ORAL

## PRAZOSIN HYDROCHLORIDE

	@	CLONMEL HLTHCARE	EQ 1MG BASE	N72705	001	May 16, 1989	Jan	DISC
	@		EQ 5MG BASE	N72707	001	May 16, 1989	Jan	DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION  
PREDNISOLONE ACETATE

	@ STERIS	25MG/ML	N83398 001	Mar	DISC
	@	50MG/ML	N83764 001	Mar	DISC
SUSPENSION/DROPS; OPHTHALMIC					
>D>	ECONOPRED PLUS				
>D>	AB FALCON PHARMS	1%	N17469 001	May	CTNA
>A>	OMNIPRED				
>A>	AB ALCON	1%	N17469 001	May	CTNA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL  
COMPAZINE

>D>	GLAXOSMITHKLINE	2.5MG	N11127 003	May	DISC
>A>	@	2.5MG	N11127 003	May	DISC
>D>		5MG	N11127 001	May	DISC
>A>	@	5MG	N11127 001	May	DISC

PROCHLORPERAZINE EDISYLATE

>D>	SYRUP; ORAL				
>D>	COMPAZINE				
>D>	GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188 001	May	DISC
>A>	@	EQ 5MG BASE/5ML	N11188 001	May	DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL  
COMPAZINE

>D>	+ GLAXOSMITHKLINE	EQ 10MG BASE	N21019 001	Oct 06, 1999	May DISC
>A>	@	EQ 10MG BASE	N21019 001	Oct 06, 1999	May DISC

PROGESTERONE

GEL; VAGINAL  
CRINONE

>A>	COLUMBIA LABS	4%	N20701 001	Jul 31, 1997	May CAHN
>A>	+	8%	N20701 002	Jul 31, 1997	May CAHN
>D>	COLUMBIA RES LABS	4%	N20701 001	Jul 31, 1997	May CAHN
>D>	+	8%	N20701 002	Jul 31, 1997	May CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL  
PHENERGAN

	@ WYETH PHARMS INC	12.5MG	N10926 002	Mar	DISC
	@	25MG	N10926 001	Mar	DISC
PROMETHAZINE HYDROCHLORIDE					
AB	+ G AND W LABS	25MG	N40428 001	Feb 05, 2002	Mar CRLD
PROMETHEGAN					
	+ G AND W LABS	50MG	N87165 001	Aug 14, 1987	Jan CRLD
SYRUP; ORAL					
PROMETHAZINE HYDROCHLORIDE					
AA	VINTAGE	6.25MG/5ML	N40643 001	Apr 26, 2006	Apr NEWA

PROPOFOL

INJECTABLE; INJECTION  
PROPOFOL

AB	HOSPIRA	10MG/ML	N77908 001	Mar 17, 2006	Mar	NEWA
----	---------	---------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL  
PROPOXYPHENE HYDROCHLORIDE

AA	PAR PHARM	65MG	N80269 001		Mar	CAHN
----	-----------	------	------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION  
PROPRANOLOL HYDROCHLORIDE

AP	SANDOZ	1MG/ML	N76400 001	Feb 26, 2003	Jan	CAHN
----	--------	--------	------------	--------------	-----	------

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION  
REGONOL

AP	SANDOZ	5MG/ML	N17398 001		Jan	CAHN
----	--------	--------	------------	--	-----	------

QUAZEPAM

TABLET; ORAL  
DORAL

>D>	@ MEDPOINTE PHARM HLC	7.5MG	N18708 003	Feb 26, 1987	May	CAHN
>D>	+	15MG	N18708 001	Dec 27, 1985	May	CAHN
>A>	@ QUESTCOR PHARMS	7.5MG	N18708 003	Feb 26, 1987	May	CAHN
>A>	+	15MG	N18708 001	Dec 27, 1985	May	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL  
QUINAPRIL HYDROCHLORIDE

AB	TORPHARM	EQ 5MG BASE	N76240 001	Jan 26, 2006	Jan	NEWA
AB		EQ 10MG BASE	N76240 002	Jan 26, 2006	Jan	NEWA
AB		EQ 20MG BASE	N76240 003	Jan 26, 2006	Jan	NEWA
AB		EQ 40MG BASE	N76240 004	Jan 26, 2006	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL  
QUINIDINE GLUCONATE

BX	+ MUTUAL PHARM	324MG	N89338 001	Feb 11, 1987	Jan	CTEC
BX	WATSON LABS	324MG	N87810 001	Sep 29, 1982	Jan	CMFD

QUINIDINE SULFATE

TABLET; ORAL  
QUINIDINE SULFATE

	@ CLONMEL HLTHCARE	200MG	N87011 001		Jan	DISC
	@ LANNETT	200MG	N83743 001		Jan	DISC
	@ MUTUAL PHARM	100MG	N81029 001	Apr 14, 1989	Jan	DISC
	@ PHARM FORM	200MG	N83808 001		Jan	DISC
	@ SANDOZ	200MG	N84631 001		Jan	DISC
	@	200MG	N84914 001		Jan	DISC
AB		200MG	N88072 002		Jan	NEWA
	@	300MG	N89839 001	Sep 29, 1988	Jan	DISC
	@ WATSON LABS	200MG	N83288 001		Jan	DISC

## TABLET; ORAL

QUINIDINE SULFATE

@ WATSON LABS

200MG

N85140 002

Jan DISC

RANITIDINE

INJECTABLE; INJECTION

RANITIDINE

AP BEDFORD

EQ 25MG BASE/ML

N77458 001 Feb 16, 2006 Feb NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

+ CV THERAP

500MG

N21526 002 Jan 27, 2006 Jan NEWA

>A> RASAGILINE MESYLATE

&gt;A&gt; TABLET; ORAL

&gt;A&gt; AZILECT

&gt;A&gt; TEVA

EQ 0.5MG BASE

N21641 001 May 16, 2006 May NEWA

&gt;A&gt; +

EQ 1MG BASE

N21641 002 May 16, 2006 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JANSSEN PHARMA

3MG

N21444 004 Dec 23, 2004 Mar CMFD

4MG

N21444 005 Dec 23, 2004 Mar CMFD

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

&gt;A&gt; SECREFLO

&gt;A&gt; + CHIRHOCLIN

16UGM/VIAL

N21136 001 Apr 04, 2002 May CTNA

&gt;D&gt; SECREMAX

&gt;D&gt; + CHIRHOCLIN

16UGM/VIAL

N21136 001 Apr 04, 2002 May CTNA

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

SOMERSET

6MG/24HR

N21336 001 Feb 27, 2006 Mar CAIN

9MG/24HR

N21336 002 Feb 27, 2006 Mar CAIN

+

12MG/24HR

N21336 003 Feb 27, 2006 Mar CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

SOMERSET

6MG/24HR

N21336 001 Feb 27, 2006 Feb NEWA

9MG/24HR

N21336 002 Feb 27, 2006 Feb NEWA

+

12MG/24HR

N21336 003 Feb 27, 2006 Feb NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

&gt;D&gt; AP B BRAUN

900MG/100ML

N17464 001

May CRLD

&gt;A&gt; AP +

900MG/100ML

N17464 001

May CRLD

&gt;D&gt; AP

900MG/100ML

N19635 002 Mar 09, 1988

May CRLD

&gt;A&gt; AP +

900MG/100ML

N19635 002 Mar 09, 1988

May CRLD

&gt;D&gt; AP

BAXTER HLTHCARE

900MG/100ML

N16677 001

May CRLD

INJECTABLE; INJECTIONSODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	AP	+	BAXTER HLTHCARE	900MG/100ML	N16677 001		May	CRLD
>D>	AP			900MG/100ML	N20178 001	Dec 07, 1992	May	CRLD
>A>	AP	+		900MG/100ML	N20178 001	Dec 07, 1992	May	CRLD
>D>	AP		HOSPIRA	900MG/100ML	N16366 001		May	CRLD
>A>	AP	+		900MG/100ML	N16366 001		May	CRLD
>D>	AP			900MG/100ML	N19465 001	Jul 15, 1985	May	CRLD
>A>	AP	+		900MG/100ML	N19465 001	Jul 15, 1985	May	CRLD
>D>	AP			900MG/100ML	N19480 001	Sep 17, 1985	May	CRLD
>A>	AP	+		900MG/100ML	N19480 001	Sep 17, 1985	May	CRLD

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

## TABLET; ORAL

## OSMOPREP

		+	SALIX PHARMS	0.398GM;1.102GM	N21892 001	Mar 16, 2006	Mar	NEWA
--	--	---	--------------	-----------------	------------	--------------	-----	------

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION

## GENOTROPIN

>D>		+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	Aug 24, 1995	May	CTEC
>A>	BX	+		5.8MG/VIAL	N20280 006	Aug 24, 1995	May	CTEC
			GENOTROPIN PRESERVATIVE FREE					
>D>			PHARMACIA AND UPJOHN	1.5MG/VIAL	N20280 004	Aug 24, 1995	May	CTEC
>A>	BX			1.5MG/VIAL	N20280 004	Aug 24, 1995	May	CTEC
>A>			OMNITROPE					
>A>	BX		SANDOZ	1.5MG/VIAL	N21426 002	May 30, 2006	May	NEWA
>A>	BX			5.8MG/VIAL	N21426 001	May 30, 2006	May	NEWA

SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE

AB			PUREPAC PHARM	25MG	N40353 003	Mar 15, 2006	Feb	NEWA
----	--	--	---------------	------	------------	--------------	-----	------

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION

## ANECTINE

AP	+	SANDOZ	20MG/ML	N08453 002			Jan	CAHN
		@	50MG/ML	N08453 003			Jan	CAHN
		@	500MG/VIAL	N08453 001			Jan	CAHN
		@	1GM/VIAL	N08453 004			Jan	CAHN

SULFACETAMIDE SODIUM

## SOLUTION/DROPS; OPHTHALMIC

## SULFACETAMIDE SODIUM

AT			ALCON	30%	N89068 001	May 05, 1987	Apr	CAHN
----	--	--	-------	-----	------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

## SUSPENSION; ORAL

## BACTRIM PEDIATRIC

AB			MUTUAL PHARM	200MG/5ML; 40MG/5ML	N17560 002		Apr	CMFD
----	--	--	--------------	---------------------	------------	--	-----	------



SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX

+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080 001	Dec 28, 1992	Feb	CDFR
	IMITREX STATDOSE					
+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)	N20080 002	Feb 01, 2006	Feb	NEWA
+		EQ 6MG BASE/0.5ML (12MG/ML)	N20080 003	Dec 23, 1996	Feb	NEWA

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

	PFIZER	12.5MG	N21938 001	Jan 26, 2006	Jan	NEWA
		25MG	N21938 002	Jan 26, 2006	Jan	NEWA
+		50MG	N21938 003	Jan 26, 2006	Jan	NEWA

>D> TECHNETIUM TC-99M APCITIDE

&gt;D&gt; INJECTABLE; INJECTION

&gt;D&gt; ACUTECT

>D>	CIS BIO INTL SA	N/A	N20887 001	Sep 14, 1998	May	DISC
>A>	@	N/A	N20887 001	Sep 14, 1998	May	DISC
		N/A	N20887 001	Sep 14, 1998	Apr	CAHN

>D> TECHNETIUM TC-99M DEPREOTIDE

&gt;D&gt; INJECTABLE; INJECTION

&gt;D&gt; NEO TECT KIT

>D>	+ CIS BIO INTL SA	N/A	N21012 001	Aug 03, 1999	May	DISC
>A>	@	N/A	N21012 001	Aug 03, 1999	May	DISC
	+	N/A	N21012 001	Aug 03, 1999	Apr	CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

&gt;D&gt; MYOVUE 30ML

>D>	+ GE HEALTHCARE	N/A	N20372 002	Jul 07, 2005	May	DISC
>A>	@	N/A	N20372 002	Jul 07, 2005	May	DISC

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

AB	+ ORTHO MCNEIL PHARM	80MG	N19641 001	May 24, 1988	Mar	CFTG
----	----------------------	------	------------	--------------	-----	------

TERCONAZOLE

AB	PERRIGO NEW YORK	80MG	N77149 001	Mar 17, 2006	Mar	NEWA
----	------------------	------	------------	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB	+ UNIMED PHARMS	1%	N21015 001	Feb 28, 2000	Jan	CTEC
----	-----------------	----	------------	--------------	-----	------

TESTOSTERONE

AB	WATSON LABS	1%	N76737 001	Jan 27, 2006	Jan	NEWA
----	-------------	----	------------	--------------	-----	------

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

	@ INDEVUS PHARMS	200MG/ML	N09165 001		Jan	CAHN
AO	+	200MG/ML	N09165 003		Jan	CAHN

INJECTABLE; INJECTION  
TESTOSTERONE ETHANATE

>A> AO PADDOCK 200MG/ML N40575 001 Jun 14, 2006 May NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

>A> @ RADIUS PHARMS 250MG N50278 003 May CAHN  
 >A> @ 500MG N50278 001 May CAHN  
 >D> @ SCIREG INTL INC 250MG N50278 003 May CAHN  
 @ 250MG N50278 003 Apr CAHN  
 >D> @ 500MG N50278 001 May CAHN  
 @ 500MG N50278 001 Apr CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION  
THALLOUS CHLORIDE TL 201

AP TRACE RADIOCHEMICALS 1mCi/ML N75569 001 Nov 21, 2001 Feb CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB NOSTRUM 400MG N40595 001 Apr 21, 2006 Apr NEWA  
 AB 600MG N40560 002 Apr 21, 2006 Apr NEWA  
 UNIPHYL  
 AB + PURDUE FREDERICK 400MG N87571 001 Sep 01, 1982 Apr CTEC  
 AB + 600MG N40086 001 Apr 15, 1996 Apr CTEC

>D> TICARCILLIN DISODIUM

>D> INJECTABLE; INJECTION

>D> TICAR

>D> + GLAXOSMITHKLINE EQ 1GM BASE/VIAL N50497 001 May DISC  
 >A> @ EQ 1GM BASE/VIAL N50497 001 May DISC  
 >D> + EQ 3GM BASE/VIAL N50497 002 May DISC  
 >A> @ EQ 3GM BASE/VIAL N50497 002 May DISC  
 >D> + EQ 20GM BASE/VIAL N50497 004 May DISC  
 >A> @ EQ 20GM BASE/VIAL N50497 004 May DISC  
 >D> + EQ 30GM BASE/VIAL N50497 005 Apr 04, 1984 May DISC  
 >A> @ EQ 30GM BASE/VIAL N50497 005 Apr 04, 1984 May DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

MISSION PHARMA 250MG N21618 001 May 17, 2004 Jan CAHN  
 + 500MG N21618 002 May 17, 2004 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ IVAX PHARMS 50MG N75963 001 Jul 03, 2002 Jan DISC

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT VINTAGE 0.025% N40671 001 Jun 09, 2006 May NEWA

	CREAM; TOPICAL							
	TRIAMCINOLONE ACETONIDE							
>A>	AT	VINTAGE	0.1%		N40671 002	Jun 09, 2006	May	NEWA
	<u>TRIAMCINOLONE DIACETATE</u>							
	INJECTABLE; INJECTION							
	ARISTOCORT							
	@ SANDOZ		25MG/ML		N11685 003		Jan	CAHN
	@		40MG/ML		N12802 001		Jan	CAHN
	<u>TRIAMCINOLONE HEXACETONIDE</u>							
	INJECTABLE; INJECTION							
	ARISTOSPAN							
	+ SANDOZ		5MG/ML		N16466 001		Jan	CAHN
	+		20MG/ML		N16466 002		Jan	CAHN
	<u>TRICHLORMETHIAZIDE</u>							
	TABLET; ORAL							
	TRICHLORMETHIAZIDE							
>D>	@ ABC HOLDING		4MG		N85568 001		May	CAHN
>A>	@ TG UNITED LABS		4MG		N85568 001		May	CAHN
	<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>							
>D>	INJECTABLE; INJECTION							
>D>	STELAZINE							
>D>	+ GLAXOSMITHKLINE		EQ 2MG BASE/ML		N11552 005		May	DISC
>A>	@		EQ 2MG BASE/ML		N11552 005		May	DISC
	<u>TRIPLENNAMINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	PBZ							
	@ NOVARTIS		50MG		N05914 002		Jan	DISC
	<u>TROLEANDOMYCIN</u>							
	CAPSULE; ORAL							
	TAO							
	@ PFIZER		EQ 250MG BASE		N50336 002		Mar	DISC
	<u>UNOPROSTONE ISOPROPYL</u>							
	SOLUTION/DROPS; OPHTHALMIC							
	RESCULA							
	+ R TECH UENO LTD		0.15%		N21214 001	Aug 03, 2000	Feb	CAHN
	<u>UROKINASE</u>							
	INJECTABLE; INJECTION							
	ABBOKINASE							
	@ IMARX THERAP		5,000 IU/VIAL		N21846 003		Apr	CAHN
	@		9,000 IU/VIAL		N21846 002		Apr	CAHN
	+		250,000 IU/VIAL		N21846 001		Apr	CAHN
>A>	<u>VARENICLINE TARTRATE</u>							
>A>	TABLET; ORAL							
>A>	CHANTIX							
>A>	PFIZER		EQ 0.5MG BASE		N21928 001	May 10, 2006	May	NEWA
>A>	+		EQ 1MG BASE		N21928 002	May 10, 2006	May	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION  
VECURONIUM BROMIDE

AP + BEDFORD 20MG/VIAL N75549 002 Jun 13, 2000 Jan CRLD

WARFARIN SODIUM

TABLET; ORAL  
WARFARIN SODIUM

>A> AB ZYDUS PHARMS USA 1MG N40663 001 May 30, 2006 May NEWA  
>A> AB 2MG N40663 002 May 30, 2006 May NEWA  
>A> AB 2.5MG N40663 003 May 30, 2006 May NEWA  
>A> AB 3MG N40663 004 May 30, 2006 May NEWA  
>A> AB 4MG N40663 005 May 30, 2006 May NEWA  
>A> AB 5MG N40663 006 May 30, 2006 May NEWA  
>A> AB 6MG N40663 007 May 30, 2006 May NEWA  
>A> AB 7.5MG N40663 008 May 30, 2006 May NEWA  
>A> AB 10MG N40663 009 May 30, 2006 May NEWA

ZIDOVUDINE

CAPSULE; ORAL  
RETROVIR

AB + GLAXOSMITHKLINE 100MG N19655 001 Mar 19, 1987 Mar CFTG

ZIDOVUDINE

AB AUROBINDO PHARMA LTD 100MG N78128 001 Mar 27, 2006 Mar NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL  
GEODON

+ PFIZER INC EQ 10MG BASE/ML N21483 001 Mar 29, 2006 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL  
ZONISAMIDE

AB GLENMARK PHARMS 25MG N77651 001 Jan 30, 2006 Jan NEWA  
AB 50MG N77651 002 Jan 30, 2006 Jan NEWA  
AB 100MG N77651 003 Jan 30, 2006 Jan NEWA  
>A> AB INVAGEN PHARMS 25MG N77869 001 May 31, 2006 May NEWA  
>A> AB 50MG N77869 002 May 31, 2006 May NEWA  
>A> AB 100MG N77869 003 May 31, 2006 May NEWA  
AB SUN PHARM INDS (IN) 25MG N77634 001 Mar 17, 2006 Mar NEWA  
AB 50MG N77634 002 Mar 17, 2006 Mar NEWA  
AB 100MG N77634 003 Mar 17, 2006 Mar NEWA  
AB WATSON LABS 25MG N77650 001 Apr 20, 2006 Apr NEWA  
AB 50MG N77650 002 Apr 20, 2006 Apr NEWA  
AB 100MG N77650 003 Apr 20, 2006 Apr NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2006**

NO MAY 2006 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2006 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>					
021652 001	5034394	Dec 18, 2011	DS DP	D-40	Aug 02, 2007
	5034394*PED	Jun 18, 2012			
	5047407	Nov 17, 2009	DS DP	U-257	
	5047407*PED	May 17, 2010			
	5089500	Jun 26, 2009		U-257	
	5089500*PED	Dec 26, 2009			
	5905082	May 18, 2016	DS DP		
	5905082*PED	Nov 18, 2016			
	6294540	May 14, 2018	DS DP	U-257	
	6294540*PED	Nov 14, 2018			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>					
021457 001				I-235	Feb 03, 2009
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>					
020983 001	6131566	Apr 14, 2015	DP	U-716	
	6131566	Apr 14, 2015	DP	U-589	
	6532955	Apr 14, 2015	DP	U-716	
	6532955	Apr 14, 2015	DP	U-590	
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>					
021762 001				NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>					
021287 001	4661491	May 27, 2007		U-706	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>					
020364 006				NS	Apr 11, 2009
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>					
020364 007				NS	Apr 11, 2009
<u>ANIDULAFUNGIN - ERAXIS</u>					
021632 001	5965525	Oct 12, 2016	DS DP	U-540	NCE Feb 17, 2011
	6384013	Mar 19, 2012	DS		
	6743777	Mar 19, 2012	DP	U-540	
	6960564	Apr 12, 2021	DP	U-540	
<u>APREPITANT - EMEND</u>					
021549 001	5145684	Jan 25, 2011	DP		
<u>APREPITANT - EMEND</u>					
021549 002	5145684	Jan 25, 2011	DP		
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 001				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 002				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 003				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 004				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 005				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 006				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021713 001	6977257	Apr 24, 2022	DS DP	I-488	Mar 01, 2008
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAINE</u>					
022010 001				NP	Mar 30, 2009
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>					
020114 001				D-102	Feb 17, 2009



**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>					
021852 001	4866048	Dec 29, 2007	DS DP	U-88	NC Jan 09, 2009
	4866048	Dec 29, 2007	DS DP	U-193	
	5763426	Jun 09, 2015	DS DP		
	6753013	Jan 27, 2020		DP U-88	
	6753013	Jan 27, 2020		DP U-193	
<u>BIVALIRUDIN - ANGIOMAX</u>					
020873 001				I-486	Nov 30, 2008
<u>BORTEZOMIB - VELCADE</u>					
021602 001				ODE	Mar 25, 2012
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>					
021770 001	5424078	Jun 13, 2012		DP	
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021		DP	
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021		DP	
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021		DP	
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021		DP	
	6673337*PED	Jan 26, 2022			
<u>BROMFENAC SODIUM - XIBROM</u>					
021664 001				I-485	Jan 27, 2009
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 001	6899099	Dec 23, 2018		U-645	
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 002	6899099	Dec 23, 2018		U-645	
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - RHINOCORT</u>					
020746 001	6986904	Apr 29, 2017	DP	U-699	
<u>BUDESONIDE - RHINOCORT</u>					
020746 002	6986904	Apr 29, 2017	DP	U-699	
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>					
021823 001				M-52	Jan 24, 2009
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>					
021485 002	>A> 4963590	Nov 27, 2007	DP	U-219	
	>A> 5112861	May 12, 2009		U-219	
	>A> 5135950	Oct 31, 2010	DS DP	U-219	
	>A> 6500867	Jun 29, 2020	DP	U-219	
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>					
021485 003	>A> 4963590	Nov 27, 2007	DP	U-219	
	>A> 5112861	May 12, 2009		U-219	
	>A> 5135950	Oct 31, 2010	DS DP	U-219	
	>A> 6500867	Jun 29, 2020	DP	U-219	
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>					
021485 001	>A> 4963590	Nov 27, 2007	DP	U-219	
	>A> 5112861	May 12, 2009		U-219	
	>A> 5135950	Oct 31, 2010	DS DP	U-219	
	>A> 6500867	Jun 29, 2020	DP	U-219	
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>					
021222 001	4839350	Apr 14, 2009	DS DP		
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 001	4525358	Jun 25, 2007	DS DP	U-565	
	4525358*PED	Dec 25, 2007			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 002	4525358	Jun 25, 2007	DS DP	U-565	
	4525358*PED	Dec 25, 2007			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>					
021150 001	7014867	Jun 10, 2022	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>					
020832 004	>A> 5690958	Sep 30, 2016	DP		
	>A> 6536975	Nov 10, 2020	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>					
020832 003	>A> 5538353	Aug 25, 2015	DP		
	>A> 5690958	Sep 30, 2016	DP		
	>A> 5752363	Apr 22, 2017	DP		
	>A> 5772346	Apr 22, 2017	DP		
	>A> D386849	Nov 25, 2011	DP		
	>A> D396911	Aug 11, 2012	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK</u>					
021555 002	5690958	Sep 30, 2016	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 002	>A> 6991393	Mar 14, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 005	>A> 5690958	Sep 30, 2016	DP		
	>A> 6536975	Nov 10, 2020	DP		
	>A> 6729786	Mar 14, 2023	DP		
	>A> 6991393	Jan 31, 2024	DP		
<u>CICLOPIROX - LOPROX</u>					
020519 001	7018656	Sep 05, 2018	DP		
	7026337	Apr 02, 2018		U-714	
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>					
021697 001	5723606	Mar 03, 2015	DS DP	U-698	
<u>DAPTOMYCIN - CUBICIN</u>					
021572 001	>A> RE39071	Jun 15, 2016	DS DP	U-728	
<u>DAPTOMYCIN - CUBICIN</u>					
021572 002	>A> RE39071	Jun 15, 2016	DS DP	U-728	
<u>DECITABINE - DACOGEN</u>					
021790 001				>A> NCE	May 02, 2011
<u>DESFLURANE - SUPRANE</u>					
020118 001	5617906	Apr 08, 2014	DP		
<u>DESLORATADINE - CLARINEX</u>					
021165 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
<u>DESLORATADINE - CLARINEX</u>					
021300 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-611	
	4659716*PED	Oct 01, 2007			
<u>DESLORATADINE - CLARINEX</u>					
021312 001	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007		U-427	
	>A> 5607697	Jun 07, 2015	DP		
<u>DESLORATADINE - CLARINEX</u>					
021312 002	4659716	Mar 31, 2007	DP	U-725	
	4659716	Mar 31, 2007	DP	U-427	
	4659716*PED	Oct 01, 2007	DP		
	>A> 5607697	Jun 07, 2015	DP		

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESCLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>					
021605 001	4659716	Mar 31, 2007	DP U-726		
	4659716	Mar 31, 2007	DP U-644		
	4659716*PED	Oct 01, 2007			
	6979463	Mar 28, 2022	DP		
<u>DESCLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>					
021313 001	4659716	Mar 31, 2007	DP U-707	NCE	Dec 21, 2006
	4659716*PED	Oct 01, 2007		NC	Mar 03, 2008
	6100274	Jul 07, 2019	DP	PED	Jun 21, 2007
	>A> 6100274*PED	Jan 07, 2020			
	6709676	Feb 18, 2021	DP U-707		
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 001	>A> 7022340	Apr 30, 2023	DP		
<u>DESMOPRESSIN ACETATE - DDAVP</u>					
019955 002	>A> 7022340	Apr 30, 2023	DP		
<u>DOCETAXEL - TAXOTERE</u>					
020449 001	5750561	Jul 03, 2012	DP	I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 001	4895841	Nov 25, 2010	DS DP U-713		
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 002	4895841	Nov 25, 2010	DS DP U-713		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>					
021676 001	5569652	Oct 29, 2013		U-1	Mar 16, 2009
	5798338	Jul 10, 2015	DP		
	6787531	Aug 31, 2020	DP		
	6933395	Aug 11, 2017	DP		
	>A> 6958326	Dec 20, 2021	DP		
	RE37564	Jun 30, 2014	DP		
	RE37838	Jun 30, 2014	DP		
	RE38253	Jun 30, 2014	DP		
<u>EFAVIRENZ - SUSTIVA</u>					
020972 001	>A> 5519021	May 21, 2013	DS DP		
	>A> 5663169	Sep 02, 2014		U-257	
	>A> 5811423	Aug 07, 2012	DS DP	U-256	
	>A> 6238695	Apr 06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>					
020972 002	>A> 5519021	May 21, 2013	DS DP		
	>A> 5663169	Sep 02, 2014		U-257	
	>A> 5811423	Aug 07, 2012	DS DP	U-256	
	>A> 6238695	Apr 06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>					
020972 003	>A> 5519021	May 21, 2013	DS DP		
	>A> 5663169	Sep 02, 2014		U-257	
	>A> 5811423	Aug 07, 2012	DS DP	U-256	
	>A> 6238695	Apr 06, 2019	DP		
<u>EFAVIRENZ - SUSTIVA</u>					
021360 002	>A> 5519021	May 21, 2013	DS DP		

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE - EMTRIVA</u>					
021500 001	>A> 5210085	May 11, 2010		>A> NCE	Jul 02, 2008
	>A> 5210085*PED	Nov 11, 2010		>A> PED	Jan 02, 2009
	>A> 5814639	Sep 29, 2015			
	>A> 5814639*PED	Mar 29, 2016			
	>A> 5914331	Sep 29, 2015			
	>A> 5914331*PED	Mar 29, 2016			
	>A> 6642245	Nov 04, 2020		U-541	
	>A> 6642245*PED	May 04, 2021			
	>A> 6703396	Mar 09, 2021	DS DP		
	>A> 6703396*PED	Sep 09, 2021			
<u>EMTRICITABINE - EMTRIVA</u>					
021896 001	>A> 5210085	May 11, 2010		U-257	>A> NDF
	>A> 5210085*PED	Nov 11, 2010			>A> NCE
	>A> 5814639	Sep 29, 2015	DS DP		>A> PED
	>A> 5814639*PED	Mar 29, 2016			>A> PED
	>A> 5914331	Sep 29, 2015	DS		
	>A> 5914331*PED	Mar 29, 2016			
	>A> 6642245	Nov 04, 2020		U-257	
	>A> 6642245*PED	May 04, 2021			
	>A> 6703396	Mar 09, 2021	DS DP		
	>A> 6703396*PED	Sep 09, 2021			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>					
021752 001	>A> 5210085	May 11, 2010		U-248	>A> NCE
	>A> 5210085	May 11, 2010		U-541	>A> PED
	>A> 5210085*PED	Nov 11, 2010			
	>A> 5814639	Sep 29, 2015	DS DP		
	>A> 5814639*PED	Mar 29, 2016			
	>A> 5914331	Sep 29, 2015	DS DP	U-248	
	>A> 5914331*PED	Mar 29, 2016			
	>A> 6642245	Nov 04, 2020		U-248	
	>A> 6642245	Nov 04, 2020		U-541	
	>A> 6642245*PED	May 04, 2021			
	>A> 6703396	Mar 09, 2021	DS DP		
	>A> 6703396*PED	Sep 09, 2021			
<u>ENTACAPONE - COMTAN</u>					
020796 001	>A> 4963590	Nov 27, 2007	DP	U-219	
	>A> 5112861	May 12, 2009		U-219	
	>A> 5135950	Oct 31, 2010	DS DP	U-219	
	>A> 6599530	Sep 14, 2018	DP	U-219	
<u>EPLERENONE - INSPRA</u>					
021437 001	4559332	Apr 09, 2007	DS DP	U-537	
<u>EPLERENONE - INSPRA</u>					
021437 002	4559332	Apr 09, 2007	DS DP	U-537	
<u>EPLERENONE - INSPRA</u>					
021437 003	4559332	Apr 09, 2007	DS DP	U-537	

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 001	4738974	Apr 19, 2007	DS DP	U-635	I-484 Nov 24, 2007
	4738974	Apr 19, 2007	DS DP	U-373	NPP Apr 28, 2009
	4738974*PED	Oct 19, 2007		U-373	
	>A> 4786505	Apr 20, 2007		DP U-373	
	>A> 4786505	Apr 20, 2007		DP U-729	
	>A> 4853230	Apr 20, 2007		DP U-729	
	>A> 4853230	Apr 20, 2007		DP U-373	
	>A> 5690960	Nov 25, 2014		DP U-729	
	>A> 5690960	Nov 25, 2014		DP U-373	
	>A> 5714504	Feb 03, 2015		DP U-729	
	>A> 5714504	Feb 03, 2015		DP U-373	
	>A> 5877192	May 27, 2014		DP U-373	
	>A> 5877192	May 27, 2014		DP U-729	
	>A> 5900424	May 04, 2016	DS	U-729	
	>A> 5900424	May 04, 2016	DS	U-373	
	>A> 6369085	May 25, 2018	DS DP	U-729	
	>A> 6428810	Nov 03, 2019		DP U-469	
	>A> 6428810	Nov 03, 2019		DP U-729	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 002	4738974	Apr 19, 2007	DS DP	U-635	I-484 Nov 24, 2007
	4738974	Apr 19, 2007	DS DP	U-373	NPP Apr 28, 2009
	4738974*PED	Oct 19, 2007		U-373	
	>A> 4786505	Apr 20, 2007		DP U-373	
	>A> 4786505	Apr 20, 2007		DP U-729	
	>A> 4853230	Apr 20, 2007		DP U-729	
	>A> 4853230	Apr 20, 2007		DP U-373	
	>A> 5690960	Nov 25, 2014		DP U-729	
	>A> 5690960	Nov 25, 2014		DP U-373	
	>A> 5714504	Feb 03, 2015		DP U-729	
	>A> 5714504	Feb 03, 2015		DP U-373	
	>A> 5877192	May 27, 2014		DP U-373	
	>A> 5877192	May 27, 2014		DP U-729	
	>A> 5900424	May 04, 2016	DS	U-729	
	>A> 5900424	May 04, 2016	DS	U-373	
	>A> 6369085	May 25, 2018	DS DP	U-729	
	>A> 6428810	Nov 03, 2019		DP U-469	
	>A> 6428810	Nov 03, 2019		DP U-729	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>					
021840 001					>A> NP May 25, 2009
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>					
021180 001	5876746	Nov 20, 2015	DP	U-514	
<u>ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35</u>					
021490 001	6667050	Apr 06, 2019	DP	U-1	
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>					
021871 001	5552394	Jul 22, 2014		U-1	NP Feb 17, 2009
<u>EXEMESTANE - AROMASIN</u>					
020753 001					>A> I-495 Oct 05, 2008
<u>EZETIMIBE - ZETIA</u>					
021445 001	>A> 7030106	Jan 25, 2022	DP		>A> I-493 May 23, 2009
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 001					PC May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 002					PC May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>					
021612 001	5545628	Jan 10, 2015		U-701	

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - LIPOFEN</u>					
021612 002	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - LIPOFEN</u>					
021612 003	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - TRICOR</u>					
021656 001	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRICOR</u>					
021656 002	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>					
021338 001				>A> NDF	May 22, 2009
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR</u>					
021704 001	RE39069	May 29, 2018	DP		
<u>FLUNISOLIDE - AEROSPAN HFA</u>					
021247 001				NP	Jan 27, 2009
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>					
021737 001	6217895	Mar 22, 2019	DP	U-708	
	6548078	Mar 22, 2019	DP	U-708	
<u>FLUOCINONIDE - VANOS</u>					
021758 001				I-487	Mar 02, 2009
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>					
021235 001	RE39030	May 29, 2017	DP	U-397	
	RE39030	May 29, 2017	DP	U-396	
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 001	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 002	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 003	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>					
021077 001	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>					
021077 002	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>					
021077 003	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FROVATRIPTAN SUCCINATE - FROVA</u>					
021006 001	5464864	Nov 07, 2015		U-436	
<u>FULVESTRANT - FASLODEX</u>					
021344 001	4659516	Oct 01, 2006			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 001				>A> NDF	Apr 01, 2008
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 002				>A> NDF	Apr 01, 2008
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>					
021615 003				>A> NDF	Apr 01, 2008
<u>GLIMEPIRIDE - AMARYL</u>					
020496 001				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 002				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 003				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 001	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 002	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 003	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>					
021859 001				NCE	Dec 02, 2010
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>					
020818 004				NS	Apr 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>					
020818 005				NS	Apr 28, 2009
<u>IBANDRONATE SODIUM - BONIVA</u>					
021455 001	4927814	Jul 09, 2007	DS DP	U-642	
	6143326	Apr 21, 2017		U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>					
021858 001	4927814	Jul 09, 2007	DS DP	U-700 NDF NCE	Jan 06, 2009 May 16, 2008

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN LYSINE - NEOPROFEN</u>					
021903	001			NE ODE	Apr 13, 2009 Apr 13, 2013
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335	001	>A> 5521184	Jan 04, 2015	>A> I-392	May 20, 2006
		>A> 5521184*PED	Jul 04, 2015	>A> I-376	Dec 20, 2005
		>A> 6894051	May 23, 2019	DS DP U-649	May 10, 2006
		>A> 6894051*PED	Nov 23, 2019	>A> NCE	May 10, 2006
				>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335	002	>A> 5521184	Jan 04, 2015	>A> I-392	May 20, 2006
		>A> 5521184*PED	Jul 04, 2015	>A> I-376	Dec 20, 2005
		>A> 6894051	May 23, 2019	DS DP U-649	May 10, 2006
		>A> 6894051*PED	Nov 23, 2019	>A> NCE	May 10, 2006
				>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588	001	>A> 5521184	Jan 04, 2015	>A> I-392	May 20, 2006
		>A> 5521184*PED	Jul 04, 2015	>A> I-376	Dec 20, 2005
		>A> 6894051	May 23, 2019	DS DP U-649	May 10, 2006
		>A> 6894051*PED	Nov 23, 2019	>A> NCE	May 10, 2006
				>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588	002	>A> 5521184	Jan 04, 2015	>A> I-392	May 20, 2006
		>A> 5521184*PED	Jul 04, 2015	>A> I-376	Dec 20, 2005
		>A> 6894051	May 23, 2019	DS DP U-649	May 10, 2006
		>A> 6894051*PED	Nov 23, 2019	>A> NCE	May 10, 2006
				>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>					
021536	001			I-489	Oct 19, 2008
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868	001	5740794	Apr 21, 2015	DP	Jan 27, 2009
		5997848	Mar 07, 2014	U-704	
		6051256	Mar 07, 2014	DP	
		6257233	May 14, 2019	U-704	
		6423344	Mar 07, 2014	DP	
		6543448	Sep 21, 2014	DP	
		6546929	May 14, 2019	U-704	
		6582728	Jun 24, 2020	DP	
		6592904	Mar 07, 2014	DP	
		6685967	Sep 11, 2018	DP	
		6737045	Mar 07, 2014	U-704	
		RE37872	Feb 12, 2010	DP	
		RE38385	Feb 12, 2010	DP	



**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 002	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704	
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019		U-704	
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019		U-704	
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014		U-704	
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>					
021527 001	6983743	May 26, 2020	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
020406 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
020406 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 002	6749864	Feb 13, 2007	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>					
021468 003	5968976	Mar 19, 2016	DP	U-613	
<u>LANTHANUM CARBONATE - FOSRENOL</u>					
021468 004	5968976	Mar 19, 2016	DP	U-613	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 001	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694	
	6315720	Oct 23, 2020		U-694	
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018		U-694	
	6561977	Oct 23, 2020		U-694	
	6755784	Oct 23, 2020		U-694	
	6908432	Aug 28, 2018		U-694	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 002	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694	
	6315720	Oct 23, 2020		U-694	
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018		U-694	
	6561977	Oct 23, 2020		U-694	
	6755784	Oct 23, 2020		U-694	
	6908432	Aug 28, 2018		U-694	
<u>LEVETIRACETAM - KEPPRA</u>					
021035 004				NPP	Jun 21, 2008
<u>LIDOCAINE; TETRACAINE - SYNERA</u>					
021623 001				>A> NC	Jun 23, 2008

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>					
021906 001	5541206	Jul 30, 2013	DS DP	U-688	
	5541206*PED	Jan 30, 2014			
	5635523	Jun 03, 2014		U-688	
	5635523*PED	Dec 03, 2014			
	5648497	Jul 15, 2014	DS DP		
	5648497*PED	Jan 15, 2015			
	5674882	Oct 07, 2014		U-688	
	5674882*PED	Apr 07, 2015			
	5846987	Dec 29, 2012		U-688	
	5846987*PED	Jun 29, 2013			
	5886036	Dec 29, 2012	DP		
	5886036*PED	Jun 29, 2013			
	6037157	Jun 26, 2016		U-688	
	6037157*PED	Dec 26, 2016			
	6703403	Jun 26, 2016		U-688	
	6703403*PED	Dec 26, 2016			
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 001	7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 002	7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 003	7011848	Sep 20, 2013		U-712	
<u>LUBIPROSTONE - AMITIZA</u>					
021908 001	5284858	Feb 08, 2011	DS DP	NCE	Jan 31, 2011
	5317032	May 31, 2011	DS DP	U-717	
	6414016	Sep 05, 2020	DS DP	U-717	
	6583174	Oct 16, 2020	DS DP		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021850 001	>A> 6489346	Jul 16, 2016	DS DP	U-623	
	>A> 6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP	U-623	
	6645988	Jul 16, 2016	DS DP	U-588	
	>A> 6699885	Jul 16, 2016		U-623	
	>A> 6699885	Jul 16, 2016		U-588	
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021850 002	>A> 6489346	Jul 16, 2016	DS DP	U-623	
	>A> 6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP	U-623	
	6645988	Jul 16, 2016	DS DP	U-588	
	>A> 6699885	Jul 16, 2016		U-623	
	>A> 6699885	Jul 16, 2016		U-588	
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>					
021884 001	5200509	Apr 06, 2010	DS		
	5681818	Oct 28, 2014		U-697	
<u>MELOXICAM - MOBIC</u>					
020938 001				ODE PED	Aug 11, 2012 Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
020938 002				ODE PED	Aug 11, 2012 Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
021530 001				I-469 ODE PED PED	Aug 11, 2008 Aug 11, 2012 Feb 11, 2013 Feb 11, 2009
<u>MEQUINOL; TRETINOIN - SOLAGE</u>					
020922 001	5194247	Dec 10, 2013	DP	U-294	

## PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 001	>A> 5002953	Sep 17, 2011	DS DP	U-690	>A> I-494
	>A> 5002953	Sep 17, 2011	DS DP	U-734	
	>A> 5002953	Sep 17, 2011	DS DP	U-691	
	>A> 5002953	Sep 17, 2011	DS DP	U-493	
	>A> 5741803	Apr 21, 2015		DP U-734	
	>A> 5741803	Apr 21, 2015		DP U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 002	>A> 5002953	Sep 17, 2011	DS DP	U-690	>A> I-494
	>A> 5002953	Sep 17, 2011	DS DP	U-734	
	>A> 5002953	Sep 17, 2011	DS DP	U-691	
	>A> 5002953	Sep 17, 2011	DS DP	U-493	
	>A> 5741803	Apr 21, 2015		DP U-734	
	>A> 5741803	Apr 21, 2015		DP U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 003	>A> 5002953	Sep 17, 2011	DS DP	U-691	>A> I-494
	>A> 5002953	Sep 17, 2011	DS DP	U-734	
	>A> 5002953	Sep 17, 2011	DS DP	U-690	
	>A> 5002953	Sep 17, 2011	DS DP	U-493	
	>A> 5741803	Apr 21, 2015		DP U-734	
	>A> 5741803	Apr 21, 2015		DP U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 004	>A> 5002953	Sep 17, 2011	DS DP	U-691	>A> I-494
	>A> 5002953	Sep 17, 2011	DS DP	U-734	
	>A> 5002953	Sep 17, 2011	DS DP	U-690	
	>A> 5002953	Sep 17, 2011	DS DP	U-493	
	>A> 5741803	Apr 21, 2015		DP U-734	
	>A> 5741803	Apr 21, 2015		DP U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 005	>A> 5002953	Sep 17, 2011	DS DP	U-690	>A> I-494
	>A> 5002953	Sep 17, 2011	DS DP	U-734	
	>A> 5002953	Sep 17, 2011	DS DP	U-691	
	>A> 5002953	Sep 17, 2011	DS DP	U-493	
	>A> 5741803	Apr 21, 2015		DP U-734	
	>A> 5741803	Apr 21, 2015		DP U-493	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 001	>A> 5958446	Dec 12, 2012		DP	>A> NDF
	>A> 6210705	Sep 30, 2018		DP U-727	
	>A> 6348211	Sep 30, 2018		DP U-727	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 002	>A> 5958446	Dec 12, 2012		DP	>A> NDF
	>A> 6210705	Sep 30, 2018		DP U-727	
	>A> 6348211	Sep 30, 2018		DP U-727	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 003	>A> 5958446	Dec 12, 2012		DP	>A> NDF
	>A> 6210705	Sep 30, 2018		DP U-727	
	>A> 6348211	Sep 30, 2018		DP U-727	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 004	>A> 5958446	Dec 12, 2012		DP	>A> NDF
	>A> 6210705	Sep 30, 2018		DP U-727	
	>A> 6348211	Sep 30, 2018		DP U-727	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>					
021026 001	4911932	Mar 27, 2007		DP U-718	NP
<u>MINOXIDIL - MEN'S ROGAINE</u>					
021812 001	6946120	Apr 20, 2019		DP U-702	NDF

## PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MODAFINIL - PROVIGIL</u>					
020717 001	4927855	May 22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov 22, 2007		ODE	Dec 24, 2005
	RE37516	Oct 06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr 06, 2015		PED	Jun 24, 2006
<u>MODAFINIL - PROVIGIL</u>					
020717 002	4927855	May 22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov 22, 2007		ODE	Dec 24, 2005
	RE37516	Oct 06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr 06, 2015		PED	Jun 24, 2006
<u>MORPHINE SULFATE - KADIAN</u>					
020616 004	5378474	Mar 23, 2010			
<u>MORPHINE SULFATE - KADIAN</u>					
020616 005	5202128	Apr 13, 2010			
	5378474	Mar 23, 2010			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>					
021085 001	4990517	Dec 08, 2011	DS DP	U-298	
	6610327	Oct 29, 2019	DP	U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>					
021277 001	4990517	Dec 08, 2011	DS DP	U-298	
	6548079	Jul 25, 2020	DP	U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>					
021598 001	4990517	Dec 08, 2011	DS DP	U-709	
	4990517*PED	Jun 08, 2012			
<u>NALTREXONE - VIVITROL</u>					
021897 001	>A> 5792477	May 02, 2017	DP	NDF	Apr 13, 2009
	>A> 5916598	May 02, 2017	DP		
	>A> 6110503	May 02, 2017	DP		
	>A> 6194006	Dec 30, 2018	DP		
	>A> 6264987	May 19, 2020	DP		
	>A> 6331317	Nov 12, 2019	DP		
	>A> 6379703	Dec 30, 2018	DP		
	>A> 6379704	May 19, 2020	DP		
	>A> 6395304	Nov 12, 2019	DP		
	>A> 6403114	May 02, 2017	DP		
	>A> 6495164	May 25, 2020	DP		
	>A> 6495166	Nov 12, 2019	DP		
	>A> 6534092	May 19, 2020	DP		
	>A> 6537586	Nov 12, 2019	DP		
	>A> 6596316	Dec 30, 2018	DP		
	>A> 6667061	May 25, 2020	DP		
	>A> 6713090	Nov 12, 2019	DP		
	>A> 6939033	Nov 12, 2019	DP		
<u>NELARABINE - ARRANON</u>					
021877 001	5747472	Feb 20, 2013		U-696	
	5747472	Feb 20, 2013		U-695	
	5747472	Feb 20, 2013		U-689	
	5821236	Feb 20, 2013		U-695	
<u>NIACIN - NIASPAN</u>					
020381 001	7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 002	7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 003	7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 004	7011848	Sep 20, 2013		U-712	

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>					
020381 005	7011848	Sep 20, 2013	U-712		
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 001				PC	Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 002				PC	Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 001	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 002	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 003	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 004	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 001	>A> 5538739	Jul 23, 2013	DP	>A> M-55	May 10, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A> 5639480	Jun 17, 2014	DP	>A> PED	Nov 10, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014			
	5688530*PED	May 18, 2015		U-268	
	>A> 5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	>A> 5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 002	5538739	Jul 23, 2013		>A> M-55	May 10, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A> 5639480	Jun 17, 2014	DP	>A> PED	Nov 10, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014			
	5688530*PED	May 18, 2015		U-268	
	>A> 5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	>A> 5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 003	5538739	Jul 23, 2013		>A> M-55	May 25, 2009
	5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A> 5639480	Jun 17, 2014	DP	>A> PED	Nov 25, 2009
	5639480*PED	Dec 17, 2014		PED	May 25, 2006
	5688530	Nov 18, 2014			
	5688530*PED	May 18, 2015		U-268	
	>A> 5922338	Jul 13, 2016	DP		
	5922338*PED	Jan 13, 2017			
	>A> 5922682	Jul 13, 2016	DP		
	5922682*PED	Jan 13, 2017			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 001	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 002	6489346	Jul 16, 2016	DS DP	U-623	
	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-623	
	6699885	Jul 16, 2016		U-588	
<u>OXALIPLATIN - ELOXATIN</u>					
021492 001	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021492 002	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 001	5420319	Aug 08, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 002	5420319	Aug 08, 2016	DS		
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 001	7037525	Feb 12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 002	7037525	Feb 12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 003	7037525	Feb 12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021285 001	>A> 7037525	Feb 12, 2018		U-724	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 001	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 002	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 003	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 004	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 005	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 006	4843086	Jun 27, 2006		U-231	
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 001				PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 002				PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>					
076056 003				PC	Oct 21, 2006
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 006	4879288	Sep 26, 2011	DS DP	U-550	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 007	4879288	Sep 26, 2011	DS DP	U-550	

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>					
020815 001	RE38968	Jul 28, 2012		U-662	
	RE38968	Jul 28, 2012		U-657	
	RE39049	Jul 28, 2012		U-662	
	RE39049	Jul 28, 2012		U-657	
	RE39050	Mar 02, 2014		U-662	
	RE39050	Mar 02, 2014		U-657	
<u>RAMIPRIL - ALTACE</u>					
019901 001	>A> 5061722	Oct 19, 2008			
<u>RANOLAZINE - RANEXA</u>					
021526 002	>A> 4567264	May 18, 2007	DS	NCE	Jan 27, 2011
	6303607	May 27, 2019		U-705	
	6369062	May 27, 2019	DP		
	6479496	May 27, 2019		U-705	
	6503911	May 27, 2019	DP		
	6525057	May 27, 2019		U-705	
	6562826	May 27, 2019		U-705	
	6617328	May 27, 2019	DP		
	6620814	May 27, 2019		U-705	
	6852724	May 27, 2019		U-705	
	6864258	May 27, 2019		U-705	
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 001				>A> NCE	May 16, 2011
<u>RASAGILINE MESYLATE - AZILECT</u>					
021641 002				>A> NCE	May 16, 2011
<u>RIFAXIMIN - XIFAXAN</u>					
021361 001	>A> 7045620	May 22, 2024	DS		
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 001				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 002				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 003				M-52	Jan 24, 2009
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 003	>A> 4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 004	>A> 4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 005	>A> 4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
020823 006	>A> 4948807	Aug 14, 2012	DS	U-322	
<u>RIVASTIGMINE TARTRATE - EXELON</u>					
021025 001	>A> 4948807	Aug 14, 2012	DS	U-322	
<u>ROCURONIUM BROMIDE - ZEMURON</u>					
020214 003	4894369	Apr 13, 2008			
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020236 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-182	
	5225445*PED	Aug 12, 2008			

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020692 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008			
<u>SELEGILINE - EMSAM</u>					
021336 001	RE34579	Aug 18, 2007	DS DP	U-711 NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 002	RE34579	Aug 18, 2007	DS DP	U-711 NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 003	RE34579	Aug 18, 2007	DS DP	U-711 NDF	Feb 27, 2009
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 001	7014846	Aug 11, 2013		DP U-246	
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 002	7014846	Aug 11, 2013		DP U-246	
<u>SIMVASTATIN - ZOCOR</u>					
019766 001	>A> RE36481 ***	Jul 10, 2007		U-300	
	>A> RE36481*PED	Jan 10, 2008		U-300	
	>A> RE36520 ***	May 26, 2009		U-300	
	>A> RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 002	>A> RE36481 ***	Jul 10, 2007		U-300	
	>A> RE36481*PED	Jan 10, 2008		U-300	
	>A> RE36520 ***	May 26, 2009		U-300	
	>A> RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 003	>A> RE36481 ***	Jul 10, 2007		U-300	
	>A> RE36481*PED	Jan 10, 2008		U-300	
	>A> RE36520 ***	May 26, 2009		U-300	
	>A> RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 004	>A> RE36481 ***	Jul 10, 2007		U-300	
	>A> RE36481*PED	Jan 10, 2008		U-300	
	>A> RE36520 ***	May 26, 2009		U-300	
	>A> RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 005	>A> RE36481 ***	Jul 10, 2007		U-300	
	>A> RE36481*PED	Jan 10, 2008		U-300	
	>A> RE36520 ***	May 26, 2009		U-300	
	>A> RE36520*PED	Nov 26, 2009		U-300	
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>					
021892 001	5616346	May 18, 2013	DP	U-715 NP	Mar 16, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 006	>A> 4968299	Jun 28, 2008	DP	>A> I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 007	>A> 4968299	Jun 28, 2008	DP	>A> I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 001	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 002	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		



# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 003	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 004				>A> I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 005	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 008	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 009	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 010	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 011	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 012	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 013	>A> 5435076	Apr 16, 2013	DP	>A> I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 001				>A> NP	May 30, 2009
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 002				>A> NP	May 30, 2009
<u>SORAFENIB TOSYLATE - NEXAVAR</u>					
021923 001				ODE	Dec 20, 2012
<u>SUNITINIB MALATE - SUTENT</u>					
021938 001	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 002	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 003	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>TACROLIMUS - PROGRAF</u>					
050708 001				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 002				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 003				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050709 001				ODE	Mar 29, 2013
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	6977077	Aug 19, 2019		U-597	

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>					
020785 001	>A> 5629327	Mar 01, 2013		U-731	
	>A> 6045501	Aug 28, 2018		U-731	
	>A> 6045501	Aug 28, 2018		U-371	
	>A> 6235756	Mar 01, 2013		U-731	
	>A> 6315720	Oct 23, 2020		U-442	
	>A> 6315720	Oct 23, 2020		U-731	
	>A> 6561976	Aug 28, 2018		U-731	
	>A> 6561976	Aug 28, 2018		U-371	
	>A> 6561977	Oct 23, 2020		U-371	
	>A> 6561977	Oct 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-732	
	>A> 6869399	Oct 23, 2020		U-733	
	>A> 6869399	Oct 23, 2020		U-731	
	>A> 6908432	Aug 28, 2018		U-371	
	>A> 6908432	Aug 28, 2018		U-731	
<u>THALIDOMIDE - THALOMID</u>					
020785 002	>A> 5629327	Mar 01, 2013		U-731	
	>A> 6045501	Aug 28, 2018		U-731	
	>A> 6045501	Aug 28, 2018		U-371	
	>A> 6235756	Mar 01, 2013		U-731	
	>A> 6315720	Oct 23, 2020		U-442	
	>A> 6315720	Oct 23, 2020		U-731	
	>A> 6561976	Aug 28, 2018		U-731	
	>A> 6561976	Aug 28, 2018		U-371	
	>A> 6561977	Oct 23, 2020		U-371	
	>A> 6561977	Oct 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-733	
	>A> 6869399	Oct 23, 2020		U-732	
	>A> 6869399	Oct 23, 2020		U-731	
	>A> 6908432	Aug 28, 2018		U-371	
	>A> 6908432	Aug 28, 2018		U-731	
<u>THALIDOMIDE - THALOMID</u>					
020785 003	>A> 5629327	Mar 01, 2013		U-731	
	>A> 6045501	Aug 28, 2018		U-731	
	>A> 6045501	Aug 28, 2018		U-371	
	>A> 6235756	Mar 01, 2013		U-731	
	>A> 6315720	Oct 23, 2020		U-442	
	>A> 6315720	Oct 23, 2020		U-731	
	>A> 6561976	Aug 28, 2018		U-731	
	>A> 6561976	Aug 28, 2018		U-371	
	>A> 6561977	Oct 23, 2020		U-371	
	>A> 6561977	Oct 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-731	
	>A> 6755784	Sep 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-371	
	>A> 6869399	Oct 23, 2020		U-732	
	>A> 6869399	Oct 23, 2020		U-733	
	>A> 6869399	Oct 23, 2020		U-731	
	>A> 6908432	Aug 28, 2018		U-371	
	>A> 6908432	Aug 28, 2018		U-731	

THYROTROPIN ALFA - THYROGEN

020898 001

**PRESCRIPTION AND OTC DRUG PRODUCT  
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>					
021395 001	RE38912	Oct 11, 2021	DP		
<u>TOPIRAMATE - TOPAMAX</u>					
020505 001	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX</u>					
020505 002	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX</u>					
020505 003	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX</u>					
020505 004	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX</u>					
020505 005	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX</u>					
020505 006	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 001	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 002	7018983	Oct 13, 2015		U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>					
020844 003	7018983	Oct 13, 2015		U-723	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 001	5153222	Oct 06, 2014		U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 002	5153222	Oct 06, 2014		U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 003	5153222	Oct 06, 2014		U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 004	5153222	Oct 06, 2014		U-455	
<u>VARENICLINE TARTRATE - CHANTIX</u>					
021928 001				>A> NCE	May 10, 2011
<u>VARENICLINE TARTRATE - CHANTIX</u>					
021928 002				>A> NCE	May 10, 2011
<u>ZANAMIVIR - RELENZA</u>					
021036 001	5648379	Jul 15, 2014		I-491	Mar 29, 2009
	5648379	Jul 15, 2014		U-721	
	5648379	Jul 15, 2014		U-274	
	6294572	Dec 15, 2014	DS DP		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
020825 001	>A> 4831031	Mar 02, 2012	DS DP	U-720	>A> I-492
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
020825 002	>A> 4831031	Mar 02, 2012	DS DP	U-720	>A> I-492
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
020825 003	>A> 4831031	Mar 02, 2012	DS DP	U-720	>A> I-492
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
020825 004	>A> 4831031	Mar 02, 2012	DS DP	U-720	>A> I-492
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
021483 001	>A> 4831031	Mar 02, 2012	DS DP	U-720	>A> I-492
	5312925	Sep 01, 2012	DS DP	U-720	
	6150366	May 27, 2019	DP	U-719	
	6245766	Dec 18, 2018		U-601	
<u>ZIPRASIDONE MESYLATE - GEODON</u>					
020919 001	>A> 4831031	Mar 02, 2012	DS DP	U-720	

## PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - ZOMETA</u>					
021223 001	4939130	Sep 02, 2012	DS DP	U-53	
<u>ZOLEDRONIC ACID - ZOMETA</u>					
021223 002	4939130	Sep 02, 2012	DS DP	U-53	

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:  
 DS = Drug Substance claim  
 DP = Drug Product claim  
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. \*PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with \*PED as was done prior to August 18, 2003. Patents with \*PED added after August 18, 2003 will not contain any information relative to the patent itself other than the \*PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. \*\*\* U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v. Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>